Pyroglutamylated amyloid beta peptides enhance non-fibrillogenic aggregation of the unmodified peptide

2016

Gregory Goldblatt
University of Central Florida

Find similar works at: http://stars.library.ucf.edu/etd

University of Central Florida Libraries http://library.ucf.edu

Part of the Biology Commons

STARS Citation

Goldblatt, Gregory, "Pyroglutamylated amyloid beta peptides enhance non-fibrillogenic aggregation of the unmodified peptide" (2016). Electronic Theses and Dissertations. 4865.
http://stars.library.ucf.edu/etd/4865

This Doctoral Dissertation (Open Access) is brought to you for free and open access by STARS. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of STARS. For more information, please contact lee.dotson@ucf.edu.
PYROGLUTAMYLATED AMYLOID BETA PEPTIDES ENHANCE NON-FIBRILLOGENIC AGGREGATION OF THE UNMODIFIED PEPTIDE

by

GREGORY L. GOLDBLATT
B.S. University of Central Florida, 2012
M.S. University of Central Florida, 2015

A dissertation submitted in partial fulfillment of the requirements
for the degree of Doctor of Philosophy
in the Burnett School of Biomedical Sciences
in the College of Medicine
at the University of Central Florida
Orlando, Florida

Spring Term
2016

Major Professor: Suren A. Tatulian
ABSTRACT

Alzheimer’s disease (AD) is accompanied by abnormal extracellular deposition of amyloid β (Aβ) peptide. This has led to the amyloid cascade hypothesis, causatively relating Aβ with AD. While Aβ deposits assume a fibrillar cross-β structure, prefibrillar oligomers of Aβ have been identified as the main cytotoxic agents in AD. Pyroglutamylated amyloid beta (AβpE) peptides are N-terminally truncated and pyroglutamylated (at Glu3 or Glu11) Aβ molecules that display enhanced cytotoxicity and represent up to 50% of total Aβ in AD brains. AβpE significantly enhances the toxicity of unmodified Aβ by an unknown mechanism. Although in situ Aβ populations are heterogeneous, the majority of studies have been conducted on single Aβ species.

Here, we examined the structural and morphological changes that occur in mixed Aβ/AβpE samples. Circular dichroism and transmission electron microscopy data indicate that Aβ_{pE3-42} forms β-sheet structure and undergoes delayed fibrillogenesis compared to unmodified Aβ_{1-42}. Further, Aβ_{pE3-42} decelerates β-sheet formation in mixed Aβ_{1-42}/Aβ_{pE3-42} samples. FTIR measurements, using ^{13}C-labeled Aβ_{1-42} and unlabeled Aβ_{pE3-42}, indicate that Aβ_{pE3-42} inhibits cross-β-sheet formation by Aβ_{1-42}, which explains the retardation of fibrillogenesis. FTIR on peptides ^{13}C-labeled at specific segments provided site specific structural information. Based on these data, the monomeric Aβ structure has been modeled as a β-hairpin stabilized by intramolecular H-bonding with an
N-terminal α-helix. These hairpins likely form higher order aggregates through ionic and hydrophobic interactions between the C-terminus of one hairpin and the N-terminus of another. Utilizing a novel technique, hydration from gas phase, we examined the α-helix to β-sheet transitions of these peptides. When combined, AβE3-42 and Aβ1-42 mutually inhibit intermolecular β-sheet formation, instead promoting formation of AβE3-42/Aβ1-42 hetero-oligomers of intramolecular H-bonding.

These hetero-oligomers displayed enhanced toxicity to PC12 cells compared to individual peptides and induced greater calcium release from lipid vesicles than unmodified Aβ. These results indicate that Aβ and AβpE mutually inhibit fibrillogenesis and stabilize hetero-oligomers of enhanced cytotoxicity, possibly through a membrane permeabilization mechanism. Collectively, our findings lead to a new concept that Aβ/AβpE hetero-oligomers, not just Aβ or AβpE oligomers, are the main cytotoxic species in AD.
This work is dedicated to my parents for everything they have done to help me get to
where I am today
ACKNOWLEDGMENTS

I would like to first and foremost acknowledge my mentor Dr. Suren A Tatulian. Your expertise and guidance have been instrumental in my education. In three short years I learned more than I could have dreamed. Through you I learned how to approach problems differently and be more objective of my own work. Thank you for making me into the scientist I am today.

To the other members of my committee, Dr. Ken Teter Dr. Bo Chen and Dr. Stephen King, I thank you for your membership on my committee; your input on this project was invaluable. You forced me to broaden my thinking making sure I did not get become too focused on things and lose sight of the bigger picture.

I would also like to graciously thank Dr. Ken Teter for the support without which I would not have been able to finish this project.

I would like to thank Dr. Bo Chen, Jaekyun Jeon and the rest of the Chen lab for your collaboration in collecting the TEM data for my project.

I would like to thank my former and current coworkers in the Tatulian lab especially Jason Matos, Jeremy Gornto, and Nabin Kandel.
# TABLE OF CONTENTS

LIST OF FIGURES ........................................................................................................... xi
LIST OF TABLES ............................................................................................................. xix
LIST OF ACCRONYMS AND ABBREVIATIONS ......................................................... xxi

CHAPTER ONE: INTRODUCTION .................................................................................. 1
Amyloid Beta Peptide .................................................................................................... 2

Current Issues in AD ....................................................................................................... 3
Shortcomings of the Amyloid Cascade Hypothesis ...................................................... 4
Pyroglutamylated Amyloid Beta .................................................................................... 6

Gaps in Knowledge of Aβ Oligomers .......................................................................... 8

CHAPTER TWO: LITERATURE SEARCH ........................................................................ 9
Genetics of AD ................................................................................................................ 9

Trisomy 21 and AD ........................................................................................................ 11

The Role of Tau in AD .................................................................................................. 11

Aβ Structural Studies .................................................................................................... 13

Amyloid Beta Fibrils ...................................................................................................... 13

Oligomeric Amyloid Beta ............................................................................................. 14

Aβ Aggregation ............................................................................................................... 15

Cell Death in AD ............................................................................................................ 16

Alteration of Mitochondrial Dynamics ....................................................................... 17
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Loss of Calcium Homeostasis</td>
<td>18</td>
</tr>
<tr>
<td>Amyloid Pore Formation</td>
<td>19</td>
</tr>
<tr>
<td>Nitrosylation of Proteins in AD</td>
<td>20</td>
</tr>
<tr>
<td>Methodology Literature Search</td>
<td>22</td>
</tr>
<tr>
<td>Review of FTIR</td>
<td>22</td>
</tr>
<tr>
<td>$^{13}$C Labeling of Proteins</td>
<td>24</td>
</tr>
<tr>
<td>CHAPTER THREE: METHODOLOGY</td>
<td>26</td>
</tr>
<tr>
<td>Cytotoxicity Assays</td>
<td>27</td>
</tr>
<tr>
<td>Membrane Calcium Release</td>
<td>28</td>
</tr>
<tr>
<td>FTIR</td>
<td>28</td>
</tr>
<tr>
<td>Curve-Fitting of FTIR Spectra</td>
<td>29</td>
</tr>
<tr>
<td>Hydration FTIR</td>
<td>30</td>
</tr>
<tr>
<td>Circular Dichroism</td>
<td>31</td>
</tr>
<tr>
<td>TEM</td>
<td>31</td>
</tr>
<tr>
<td>CHAPTER FOUR: RESULTS</td>
<td>32</td>
</tr>
<tr>
<td>Pyroglutamylated Amyloid-β Peptide Reverses Cross β-Sheets by a Prion-Like Mechanism</td>
<td>32</td>
</tr>
<tr>
<td>Circular Dichroism of Aβ Proteins</td>
<td>32</td>
</tr>
<tr>
<td>TEM of Aβ Fibrils</td>
<td>35</td>
</tr>
</tbody>
</table>
LIST OF FIGURES

Figure 1. Potential pathway for the pathogenesis of AD via Aβ oligomers. Little is known about the aspects of this pathway contained within the blue box. ................................. 6

Figure 2. A) Schematic depiction of the experimental set-up. Nitrogen gas is pumped through simmering D₂O into the sample compartment. Only two of four flasks with D₂O are shown for simplicity. Two sample holders are mounted vertically, at 90 degrees, one with two peptides at opposite sides of a CaF2 window and one with both peptides blended at one side. Consecutive FTIR spectra of the two samples are measured while the sample holder frame is turned back and forth by 90 degrees. Red arrows represent the infrared light. B) Photograph of the FTIR spectrometer during an actual experiment. The inset (middle bottom) provides a glimpse into the sample compartment.......................... 30

Figure 3. (A) CD spectra of Aβ₁₋₄₂ (red), AβₚE3₋₄₂ (blue) their 9:1 (teal) and, equimolar (green) ratios in HFIP at a peptide concentration of 50 µM. (B) CD spectra of the same peptides following HFIP removal via N₂ drying and vacuum desiccation...................... 33

Figure 4. CD spectra of Aβ₁₋₄₂ (A), AβₚE3₋₄₂ (B), their 9:1 (Aβ₁₋₄₂/AβₚE3₋₄₂) (C) and, equimolar (D) ratios in 50 mM phosphate 50 mM NaCl buffer pH 7.2 Spectra are shown 10 minutes (red), 1 hour (green), 2 hours (blue) and, 24 hours (pink) after addition of buffer. Final peptide concentration was 50 µM and aggregation took place at 37₀C with constant stirring. For Aβ₁₋₄₂ the spectra in pink corresponds to 17h as subsequent time points gave
weak signal due to evaporation of the sample. Spectra were cut at 210 nm due to weak
signal from Cl and peptide absorbance. ................................................................. 35

Figure 5. TEM images of Aβ1−42 (a, e, i, m), AβpE3−42 (b, f, j, n), AβpE3−42/Aβ1−42 = 1:9 (c, g, k, o), and AβpE3−42/Aβ1−42 = 1:1 (d, h, l, p) incubated in aqueous buffer of 50 mM NaCl + 50 mM Na,K-phosphate (pH 7.2) for 2 h (a−d), 4 h (e−h), 12 h (i−l), and 24 h (m−p) at 37 °C with constant stirring. The horizontal bar in each panel equals 100 nm. ....................... 37

Figure 6. FTIR spectra of AβpE3−42 (Light Blue) and uniformly 13Clabeled Aβ1−42 (Green) dried from a 200 μM HFIP solution on a CaF2 Window. The amide I area of spectra was normalized................................................................. 39

Figure 7. FTIR spectra of AβpE3−42 and uniformly 13CAβ1−42 at 1:9 molar ratio (A and B) and 1:1 molar ratio (C). Green and Red lines are experimental spectra of a sample prepared in HFIP, followed by solvent removal by desiccation and exposure to atmosphere for 10 and 20 min, respectively. The Blue is the weighted sum of the spectra of each peptide measured individually, exposed to the atmosphere for 15 min. Construction of the weighted sum spectra is described under Figure 4. Panel B is a zoom-in into the amide I/II region of spectra shown in panel A. ................................................................. 41

Figure 8. FTIR spectra of Aβ1−42 (A) and AβpE3−42 (B) in 10 mM Na,K-phosphate in D2O, pD 7.2. Change from Blue to Red corresponds to time of exposure of the peptides to the buffer for 10, 30, 50, 70, 90, and 120 min. ................................................................. 42

Figure 9. FTIR spectra of AβpE3−42 and 13CAβ1−42 combined at 1:9 (A) and 1:1 (B) molar ratios, incubated in a D2O-based phosphate buffer (pD 7.2) for 2 h, at a total peptide
concentration of 100 μM. Red and Blue lines are the experimental spectra obtained on the
two peptides combined in one sample and the weighted sums of individual spectra,
respectively. The weighted sums were obtained as $A = \Sigma f_i A_i$, where $f_i$ is the molar fraction
and $A_i$ is the absorbance spectrum of each individual peptide measured separately. Figure 10. (A) FTIR spectra of dry peptides in the amide I regions. Spectra for unlabeled
and isotopically labeled $\text{A}β_{1-42}$ and $\text{A}β_{pE3-42}$ peptides and their 1:1 combinations are
presented. Gray dotted lines correspond to $\text{A}β_{pE3-42}$, and solid black lines correspond either
to $\text{Ab}_{1-42}$ or to combined samples, as indicated. KLV or VGGV imply the peptides have
been labeled at $K^{16}L^{17}V^{18}$ or $V^{36}G^{37}G^{38}V^{39}$, respectively. In KLV/VGGV or VGGV/KLV
samples, the first stretch applies to $\text{A}β_{1-42}$ and the second to $\text{A}β_{pE3-42}$. (B) Second derivatives
of the corresponding FTIR spectra. Figure 11. FTIR spectra of 50 mM $\text{A}β_{1-42}$ (Green) $\text{A}β_{pE3-42}$ (blue) and their equimolar
combination (Red) in 50 mM phosphate + 50 mM NaCl pH 7.2 (ABC) and in 10 mM
phosphate pH 6.8 (DEF) buffers. Time points shown are 10 minutes (A,D) 60 minutes
(B,E) and 120 minutes (C,F). Total peptide concentration is 50 μM Figure 12. Difference FTIR spectra of $\text{A}β_{1-42}$ and $\text{A}β_{pE3-42}$ peptides and their equimolar
combinations in 50 mM NaCl + 50 mM phosphate buffer (A, B) and 10 mM phosphate
buffer (C, D), pH Spectra in A) and C) show the difference $\text{A}β_{1-42} - \text{A}β_{pE3-42}$, and those in
B) and D) show the difference between 1:1 combination and the normalized sum of the
spectra of the two peptides. Blue, green, and red correspond to the peptide samples
incubated in a D\textsubscript{2}O-based buffer for 10, 60 and 120 min, respectively. Total peptide concentration is 50 μM.

Figure 13. FTIR spectra of Aβ\textsubscript{1-42} (A,D), Aβ\textsubscript{pE3-42} (B,E) and, their 1:1 combination (C,F) after 10 minutes in 50 mM phosphate 50 mM NaCl pD 7.2 (A,B,C) and 10 mM phosphate pD 7.2 (D,E,F) buffers. Colors correspond to unlabeled peptide (Red) as well as proteins \textsuperscript{13}C- and \textsuperscript{15}N- labeled at K\textsuperscript{16}L\textsuperscript{17}V\textsuperscript{18} (Blue) and V\textsuperscript{36}G\textsuperscript{37}G\textsuperscript{38}V\textsuperscript{39} (green). Total peptide concentration is 50 μM.

Figure 14. FTIR spectra of Aβ\textsubscript{1-42} (green), Aβ\textsubscript{pE3-42} (blue) and, their equimolar (red) combinations after 10 (A,D) 60 (B,E) and, 120 (C,F) minutes in 50 mM phosphate 50 mM NaCl pD 7.2 buffer. Peptides are \textsuperscript{13}C- and \textsuperscript{15}N-labeled at K\textsuperscript{16}L\textsuperscript{17}V\textsuperscript{18} (A,B,C) and V\textsuperscript{36}G\textsuperscript{37}G\textsuperscript{38}V\textsuperscript{39} (D,E,F). Total peptide concentration is 50 μM.

Figure 15. FTIR spectra of Aβ\textsubscript{1-42} (green), Aβ\textsubscript{pE3-42} (blue) and, their equimolar (red) combinations after 10 (A,D) 60 (B,E) and, 120 (C,F) minutes in 10 mM phosphate pD 7.2 buffer. Peptides are \textsuperscript{13}C- and \textsuperscript{15}N-labeled at K\textsuperscript{16}L\textsuperscript{17}V\textsuperscript{18} (A,B,C) and V\textsuperscript{36}G\textsuperscript{37}G\textsuperscript{38}V\textsuperscript{39} (D,E,F). Total peptide concentration is 50 μM.

Figure 16. Second derivative of FTIR spectra taken 10 minutes after the addition of A) 50 mM phosphate + 50 mM NaCl pD 6.8 and B) 10 mM Phosphate buffer pD 6.8. For spectra labeled KLV/VGGV or VGGV/KLV the first corresponds to Aβ\textsubscript{1-42} and the second to Aβ\textsubscript{pE3-42}.
Figure 17. The amino acid sequence of Aβ_{1-42} arranged in a structure involving a β-hairpin stabilized by D^{23}-K^{28} ionic bridge, and an N-terminal stretch that may assume α-helical conformation. The isotopically labeled amino acids are shaded. Underneath is a ribbon model for Ab monomer, composed of a β-hairpin and an N-terminal α-helix. The segments K^{16}L^{17}V^{18} and V^{36}G^{37}G^{38}V^{39} are both involved in the β-hairpin and are marked by dark blue colors.

Figure 18. Schematic models for Aβ oligomerization through interactions between the core β- hairpin structures. Two arrows in each molecule represent two β-strands, connected by a loop or turn. The monomers are colored gray and pink, and the isotopically labeled segments are indicated by darker color. In all cases, the structures are stabilized by intramolecular H-bonding and intermolecular non-H-bonding contacts, i.e. ionic and/or hydrophobic interactions. The plane of the picture is parallel to the hairpin plane. In A,B the aggregation axis is perpendicular, and in C-F it is coplanar to the picture plane.

Figure 19. FTIR spectra of 50 μM Aβ_{pE3-42} (red) and ^{13}C Aβ_{1-42} (blue) in HFIP added to FTIR windows followed by HFIP removal by vacuum desiccation.

Figure 20. FTIR Spectra of Aβ_{pE3-42} sample in D_{2}O absorbance region at various times of continuous injection of D_{2}O-saturated nitrogen. The intensity of D_{2}O asymmetric stretching vibrational-rotational mode increases as D_{2}O vapor is being pumped into the sample compartment of the FTIR instrument. The spectra have been stacked for clarity.
Figure 21. FTIR spectra of $^{13}\text{C-} \alpha\beta_{1-42}$ (A) and $\alpha\beta_{pE3-42}$ (B) dried on a CaF$_2$ window (black lines) and upon injection of D$_2$O-saturated nitrogen for ~5 hours (blue to red). Amide I areas have been normalized. Time points of consecutive spectra can be determined from data of Fig. 21. The second derivatives of spectra corresponding to the dry and after five hours of vapor hydration for the $\alpha\beta_{1-42}$ (C) and $\alpha\beta_{pE3-42}$ (D)................................. 69

Figure 22. Dependence of β-structure formation (red) in $^{13}\text{C-} \alpha\beta_{1-42}$ (A) and $\alpha\beta_{pE3-42}$ (B) and amide II intensities (blue) on time of pumping D$_2$O-saturated nitrogen into the sample compartment. ................................................................. 70

Figure 23. FTIR spectra of the dried peptides at a 9:1 (A) and 1:1 (B) ratios. The teal spectra corresponds to separated peptides while the green is the peptides in combination. Amide I areas have been normalized. ................................................................. 71

Figure 24. FTIR spectra of $\alpha\beta_{pE3-42}$ and $^{13}\text{C-} \alpha\beta_{1-42}$ peptides at opposite sides of a CaF$_2$ window (A) or combined on the same side of a window (B) at a 9:1 mole ratio. Black lines are spectra of dry samples. Change in color from blue to red corresponds to injection of D$_2$O-saturated nitrogen for ~5 hours. Amide I areas have been normalized. Time intervals between consecutive spectra can be determined from data of Fig. 26. C,D) Second Derivative of FTIR spectra after 5 minutes (blue) and 5 hours (red) of hydration for both separate (C) and combined (D) peptides................................................................. 73

Figure 25. FTIR spectra of $\alpha\beta_{pE3-42}$ and $^{13}\text{C-} \alpha\beta_{1-42}$ peptides at opposite sides of a CaF$_2$ window (A) or combined on the same side of a window (B) at a 1:1 mole ratio. Black lines are spectra of dry samples. Change in color from blue to red corresponds to injection of
D$_2$O-saturated nitrogen for ~5 hours. Amide I areas have been normalized. Time intervals between consecutive spectra can be determined from data of Fig. 26. C,D) Second Derivative of FTIR spectra after 5 minutes (blue) and 5 hours (red) of hydration for both separate (C) and combined (D) peptides. .......................... 76

Figure 26. FTIR spectra for 9:1 (A) and 1:1 (B) molar ratios taken after 5 hours of continuous vapor hydration. The teal spectra corresponds to separated peptides while the green is the peptides in combination. .......................... 77

Figure 27. Changes in β-sheet/α-helix amide I intensity ratios with time of pumping D$_2$O-saturated nitrogen. A, B: Aβ$_{pE3-42}$/13C-Aβ$_{1-42}$ = 1:9; C,D: Aβ$_{pE3-42}$/13C-Aβ$_{1-42}$ = 1:1. A, C: peptides are physically separated, i.e. are at opposite sides of a CaF$_2$ window, B, D: peptides are combined at one side of a CaF$_2$ window. Symbols in A are identical to B, and symbols in C is identical to D. Black graphs describe transitions in Aβ$_{pE3-42}$, red graphs describe transitions in 13C-Aβ$_{1-42}$. Aβ$_{pE3-42}$ and 13C-Aβ$_{1-42}$ .......................... 80

Figure 28. Scheme for aggregation of Aβ$_{pE3-42}$ (gray), Aβ$_{1-42}$ (red), and their combination, accompanied with an α-helix to β-sheet transition. At the N-terminus of Aβ$_{1-42}$ there are 3 additional charges, a positive charge of the N-terminal α-amino group and 2 negative charges of the side chains of Asp1 and Glu3. Helices are shown as spirals, β-strands as arrows, and H-bonds as black bars. .......................... 82
Figure 29. Change in cellular viability caused by Ab aggregates as demonstrated by MTS assay. Studies were conducted in triplicate and normalized so that the control is equivalent to 100% viability................................................................. 83

Figure 30. Vesicular calcium release as assayed by quin-2. Aβ peptides were added to vesicles after 2 hours (A) and 24 hours (B) of aggregation via stirring at 37 °C. Data for release via Aβ1-42 (blue), AβpE3-42 (red), 9:1 (green) 1:1 (teal) and buffer control (black) are shown. Peptides were added following two measurements to establish a baseline, triton-X was added to the control after 6 measurements to pop vesicles and measure maximum fluorescence. ................................................................. 84

Figure 31. Update of Figure 1 using data collected during this work. Mixed populations of Ab1-42 and AbpE3-42 promote formation of hetero-oligomers via a non-fibrillogenic pathway. These oligomers display increased cytotoxicity to PC12 cells possibly through the formation of calcium permeable membrane pores leading to loss of Ca^{2+} homeostasis. ........................................................................................................ 90
**LIST OF TABLES**

Table 1. Characteristic amide I wavenumber relative extinction coefficients, and integrated absorbance extinction coefficients (B) of various protein secondary structures in D$_2$O, integrated extinction coefficient come from (199). ................................................................................................................. 25

Table 2. Relative amide I content of the $^{13}$C labeled peaks in peptides dried from HFIP. In the columns with two different labels the first one corresponds to A$\beta_{1-42}$ and the second to A$\beta_{pE3-42}$........................................................................................................................................................................ 48

Table 3. Secondary structures of A$\beta_{1-42}$, A$\beta_{pE3-42}$, and their equimolar combination in 50 mM phosphate 50 mM NaCl pD 6.8 (light blue) and 10 mM phosphate pD 6.8 (unshaded) determined by curve fitting of amide 1 spectra. Numbers shown are averages taken after 10, 60, and 120 minutes in buffer. Other refers to all other peaks fit and is primarily composed of unordered structure........................................................................................................................................ 53

Table 4. Quantitative data describing $\alpha$-helix to $\beta$-sheet transitions in A$\beta_{pE3-42}$ and $^{13}$C-A$\beta_{1-42}$ peptides at opposite sides of a CaF$_2$ window or combined together at one side of a window at 1:9 or 1:1 molar ratios. $\Delta$v is the shift in wavenumbers from $\alpha$-helix to $\beta$-sheet and $\Delta\Delta$v is the difference between combined and separated samples. A$_{\text{intra}}$ and A$_{\text{inter}}$ correspond to the major b-sheet peaks as found experimentally and shown in the table. 78

Table 5. Distribution of secondary structures in 50 mM phosphate 50 mM NaCl pD 6.8 as calculated by curve fitting. Numbers are the averages at 10, 60, and 120 minutes in buffer, label combination refers to the fraction of the peak corresponding to the $^{13}$C-label in
KLV/VGG and VGGV/KLV spectra. Components counted as other, primarily unordered structure, are not included in the table.

Table 6. Distribution of secondary structures in 10 mM phosphate pH 6.8 as calculated by curve fitting. Numbers are the averages at 10, 60, and 120 minutes in buffer, label combination refers to the fraction of the peak corresponding to the $^{13}$C-label in KL/VGG and VGGV/KLV spectra. Components counted as other, primarily unordered structure, are not included in the table.
LIST OF ACCRONYMS AND ABBREVIATIONS

Adenosine tri phosphate (ATP)

Alzheimer’s disease (AD)

Amyloid beta (Aβ)

Amyloid beta 1-40 (Aβ1-40)

Amyloid beta 1-42 (Aβ1-42)

Amyloid precursor protein (APP)

APP intracellular domain (AICD)

Apolipoprotein E (ApoE)

Blood brain barrier (BBB)

Calcium induced calcium release (CICR)

Cellular prion protein (PrPc)

Cerebral amyloid angiopathy (CAA)

Circular dichroism (CD)

Cyclin dependent kinase 5 (Cdk5)
Down syndrome (DS)

Dynamin related protein 1 (drp1)

Endoplasmic reticulum (ER)

Eukaryotic elongation factor 2 (eEF2)

Familial Alzheimer’s disease (FAD)

Fourier transform infrared spectroscopy (FTIR)

Glutaminyl cyclase (QC)

Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)

Guanosine tri phosphate (GTP)

Hexafluoro Isopropanol (HFIP)

Inducible nitric oxide synthase (iNOS)

Long-term potentiation (LTP)

Low density lipoprotein receptor-related protein 1 (LRP1)

Metabotropic glutamate receptor 5 (MGluR5)

Neurofibrillary tangles (NFTs)

Neuronal nitric oxide synthase (nNOS)
N-methyl D-aspartate receptor (NMDAR)

Nitric oxide (NO)

Nitric oxide synthase (NOS)

Nuclear magnetic resonance (NMR)

Presenilin 1 (PSEN1)

Presenilin 2 (PSEN2)

Pyroglutamylated amyloid beta (pE-Aβ)

Pyroglutamylated amyloid beta 3-42 (AβpE3-42)

Reactive nitridative species (RNS)

Reactive oxidative species (ROS)

Ryanodine receptor 3 (RyR3)

S-nitrosylation (SNO)

Solid-State Nuclear Magnetic Resonance (ssNMR)

Sporadic Alzheimer’s disease (SAD)

Very low density lipoprotein receptor (VLDLR)

1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC)
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol (POPG)
CHAPTER ONE: INTRODUCTION

Alzheimer’s disease (AD) is a neurodegenerative disease affecting more than 35 million people worldwide. The primary symptom of AD is progressive loss of memory and other cognitive faculties leading to death within 3-9 years of diagnoses (1). AD is the most common form of dementia representing over 50% of cases examined at autopsy or clinical series (1). AD primarily affects the elderly. The odds of being diagnosed with AD double every 5 years after the age of 65, and the odds of receiving a positive diagnosis after the age of 85 is 1:3 (2). Due to an aging population, the number of cases of AD in the United States is rising rapidly. By 2050 there will be an estimated 13 million cases representing a yearly economic cost of $1 trillion (3).

Effective treatments for AD are lacking and the success rate of AD drugs in clinical trials falls below 1% (4). There is significant loss of neuronal synapses in AD correlating closely with cognitive symptoms and predating neuronal death (5). Familial Alzheimer disease (FAD) is caused by genetic mutation with symptoms generally appearing in the early 40s. Sporadic Alzheimer disease (SAD), which makes up the majority of AD cases, usually manifests after the age of 65. FAD and SAD are indistinguishable from one another histologically. The two main hallmarks of AD are beta amyloid plaques and neurofibrillary tangles (NFTs). Plaques are extracellular protein aggregates composed of the Aβ peptide; NFTs are intracellular aggregates consisting largely of hyper-phosphorylated tau. Aβ peptides are small, hydrophobic peptides of no known physiological function, while tau normally associates with microtubules.
The amyloid cascade hypothesis states that AD is a consequence of the buildup of Aβ peptides, through either increased production or decreased clearance (6). Evidence points to soluble aggregates of Aβ as the cytotoxic species in AD (7, 8).

**Amyloid Beta Peptide**

Aβ peptides are formed by cleavage of the amyloid precursor protein (APP) a transmembrane glycoprotein. The N-terminus of the APP is in extracellular space, while the C-terminus terminates within the cytosol. The exact function of the APP is unknown, but it is believed to play a role in cell growth and proliferation, as well as influencing synaptogenesis (9). In the non-amyloidogenic pathway, the APP is cleaved by α-secretase in the middle of the amyloid beta transmembrane segment creating the C83 fragment. The C83 fragment is then cleaved by γ-secretase forming the APP Intracellular Domain (AICD) and a truncated Aβ fragment known as p3 (9-11). The AICD enters the cytosol and is believed to play a role in nuclear signaling while the p3 seems pathologically irrelevant. Interaction between β-secretase and the APP can lead to amyloidogenic cleavage at D\(^{672}\) freeing the N-terminus of the Aβ and creating the C99 fragment (12). The C99 fragment is then cleaved by γ-secretase freeing the Aβ peptide and forming the AICD (8, 10). This cleavage most frequently occurs at V\(^{40}\) forming the Aβ\(_{1-40}\) fragment, but cleavage also occurs at nearby A\(^{42}\) and G\(^{38}\) positions on the C99 forming the Aβ\(_{1-42}\) and Aβ\(_{1-38}\) respectively (12-14). The Aβ peptide leaves the membrane and enters the extracellular space.
following cleavage (10, 11, 14). Most mutations associated with FAD are associated with Aβ production and involve the APP or its processing (15-19). There are many different species of Aβ peptide and in situ Aβ populations are heterogeneous (13, 20). Although the most common Aβ found in the brain is the Aβ_{1-40} the Aβ_{1-42} is most often associated with AD (13, 21). Additionally, pyroglutamylated Aβ is a major species in the AD brain and has been found to make up to 50% of the soluble Aβ load (13, 20, 22). Amyloid beta builds up intracellularly as well, through production at either the endoplasmic reticulum (ER) or vesicles, as well as re uptake of oligomers (23-26). The intracellular buildup of Aβ often precedes extracellular increases in Aβ concentration and onset of synaptic dysfunction (24, 25).

**Current Issues in AD**

No current treatments exist that delay the progression of AD. Currently, five drugs are FDA approved for the treatment of AD, the cholinesterase inhibitors: Tacrine, Donepezil, Revastigmine, and Galantamine; and the N-methyl-D-aspartate (NMDA) receptor antagonist Memantine. There have been no new AD drugs approved since 2003 (4). Between 2002 and 2012, only one of the 230 compounds assessed for the treatment of AD passed phase 3 clinical trials and was approved for treatment(4). This failure rate of 99.6% is the highest of any therapeutic area (27, 28). High profile AD drug failures include the anti Aβ monoclonal antibody drugs bapineuzumab and solanezumab. As well as the Aβ reducing drugs Phenserine, which reduces APP expression (29),
and Flurizan, which reduces Aβ_{1-42} levels, likely through a mechanism involving γ-secretase (30, 31). Data has not been released as to whether these drugs failed to have an effect on Aβ load, or whether they decreased Aβ load, but there was no corresponding decrease in cognitive decline. The failure of these drugs to translate from animal models into humans calls into question the accuracy of existing AD models and necessitates re-evaluation of the amyloid cascade hypothesis.

Shortcomings of the Amyloid Cascade Hypothesis

In the decades since the amyloid cascade hypothesis was first postulated, many new discoveries have been made. (32-35). Recent findings have shifted focus from insoluble fibrils to soluble oligomers of Aβ as the main cytotoxic entity in AD. Soluble oligomers of Aβ have been shown to inhibit long-term potentiation (LPT), and the population of soluble oligomers is an accurate predictor of synaptic decline (7, 8, 23, 36-39). Additionally, plaque levels do not correlate with disease state and are found in the brains of cognitively normal patients (40, 41). In fact, cognitive impairment in AD correlates better with tangle burden than plaque levels (42). Additionally, studies have found Aβ neurotoxicity to be tau dependent, both in vivo and in vitro casting doubt on the completeness of the amyloid cascade hypothesis (43-45). Studies have shown oligomers to be significantly more cytotoxic than fibrils (46, 47). Some of these oligomers may be intermediates of fibrillogenesis, however others are formed via distinct pathways (48, 49). Neurotoxic oligomers appear to propagate via a prion-like mechanism, with pyroglutamylated
amyloid beta (AβpE) in particular having a profound effect on toxicity even at low molar ratios (44, 50, 51). Dot blot experiments have shown that hybrid Aβ_{pE3-42}:Aβ_{1-42} oligomers and similar sized oligomers formed by Aβ_{1-42} alone are distinct structurally with hybrid oligomers having significantly enhanced toxicity (44). Surprisingly, Aβ monomers appear neuroprotective, against both oxidative stress as well as the absence of insulin (52, 53). Aβ_{1-40} has demonstrated a protective effect by inhibition of Aβ_{1-42} aggregation (52). These findings necessitate the altering of the amyloid cascade hypothesis, shifting focus from large fibrillar aggregates to small soluble oligomers of Aβ. An illustration of this refined amyloid cascade where oligomers formed as intermediates during fibrillogenesis or via other aggregation pathways lead to AD is shown in Figure 1. Little is known about the Aβ peptide following cleavage from the membrane and prior to formation of proto-fibrils.
Figure 1. Potential pathway for the pathogenesis of AD via Aβ oligomers. Little is known about the aspects of this pathway contained within the blue box.

Pyroglutamylated Amyloid Beta

The N-truncated, N-modified pyroglutamylated Aβ (AβpE) is a major Aβ species in the AD brain and can make up as much as 50% of total soluble Aβ load (13, 20, 22, 54). Pyroglutamylation occurs when glutamic acid is at the N-terminus of the peptide, most often due to upstream aminopeptidase degradation. The N-terminal glutamic acid is then cyclized in a
dehydration reaction carried out via glutaminyl cyclase (QC) (55). Pyroglutamylated Aβ are believed to be highly involved in the pathogenesis of AD (20, 44, 54, 56). Aβ population changes over time with the fraction of AβpE increasing with disease progression (20, 57). In addition, QC expression is found in the peripheral blood of AD patients (58). The most common AβpE is the AβpE3-42 fragment, however AβpE11-42, AβpE3-40, and AβpE11-40 have all been observed in AD brains (20, 59, 60).

Over expression of QC in mice was found to cause behavioral deficits while knockout or inhibition of QC had a rescue effect (55, 61). Loss of calcium homeostasis, an early event in AD, has been shown to increase QC expression leading to an increased in AβpE production (62). Studies indicate that AβpE has altered aggregation, forming greater numbers and longer lived oligomers compared to unmodified Aβ (63, 64). Pyroglutamylated Aβ and hybrid Aβ1-42/AβpE3-42 oligomers display increased toxicity when compared to unmodified Aβ (44, 56). Additional studies found AβpE to be more resistant to astrocyte degradation and have increased cytotoxicity to cultured neurons compared to both Aβ1-42 and Aβ1-40 (22). A correlation between AβpE and adjacent deposits of hyper-phosphorylated tau has been found in AD brains, providing evidence of a link between AβpE and tau phosphorylation (56). This is strong evidence towards the involvement of AβpE in AD.
Gaps in Knowledge of Aβ Oligomers

Although they are believed to be the cytotoxic species in Aβ, structural data on Aβ oligomers is lacking. Previous structural studies have often used non-physiological conditions calling into question the disease relevance of their results (65, 66). Additionally, most structural studies have taken place on a single species of Aβ, and not a heterogeneous population as is found in situ. More detailed structural understandings of Aβ oligomers and early aggregates are necessary to better understand the role of these oligomers in the pathogenesis of AD. Of particular interest are the changes that occur in mixed samples of AβpE and Aβ. This work aimed to characterize structural and morphological changes exerted on Aβ by AβpE. We found that AβpE and Aβ mutually inhibit fibrillogenesis by inhibiting intermolecular β-sheet formation of one another. Instead, in combination they form hetero-oligomers composed of β-hairpins which aggregate through ionic or hydrophobic bonds of a C-terminus of one hairpin and the N-terminus of another. These hetero-oligomers had increased cytotoxicity to PC12 cells. This study highlights the importance of Aβ: AβpE hetero-oligomers in the pathogenesis of AD. These hetero-oligomers may represent a promising target in the search for promising new ways to effectively treat AD.
CHAPTER TWO: LITERATURE SEARCH

Before moving forward with this project, it was necessary to re-evaluate the amyloid cascade hypothesis to ensure the pertinence of Aβ peptides in AD. Research was conducted on the genetics of AD, as well as the role tau plays in AD. This data supports Aβ peptides as the initiator of AD pathology. In addition, current literature was searched on the structure and aggregation of Aβ, especially oligomeric Aβ. Finally, as this project related Aβ to the neuronal death associated with AD, it is necessary to examine current literature on possible mechanisms of neurotoxicity in AD.

Genetics of AD

Since the discovery of the first genetic link in AD, multiple genes have been implicated in AD, with many mutations found to be fully penetrant. The most prevalent FAD mutations occur on the APP, PSEN1, and PSEN2, all genes associated with production of Aβ (67, 68). One of the first genes associated with AD was the APP on chromosome 21. Many different mutations have been identified on the APP most of them leading to FAD (15, 16, 69, 70). Some APP mutations are neuroprotective, and hypothesized mechanisms of protection include: the lowering of Aβ load, inhibition of the APP transforming growth factor β2 (TGFβ2) cell mediated death pathway, or through the alteration of aggregation kinetics (15, 71).
Conversely, APP mutations implicated in FAD have been linked to: higher Aβ production, increased levels of tau, and increases in the Aβ₁₋₄₂/Aβ₁₋₄₀ ratio (16, 70). The majority of FAD mutations are linked to presenilin protein mutations (17). Mutations have been found for both PSEN1 located on chromosome 14 and PSEN2 located on chromosome 1 (17, 18, 72). PSEN 1 and 2 along with the accessory proteins nicastrin, APH-1, and PEN2 form the γ-secretase, which is responsible for the final cleavage of Aβ from the membrane. The prevailing proposed mechanism of PSEN mutations causing FAD is through partial loss in function of γ-secretase activity, leading to only partial processing of Aβ₁₋₄₂ and increasing the Aβ₁₋₄₂/Aβ₁₋₄₀ ratio in the brain (19, 68, 73).

The previously discussed genes have been linked to FAD, which represents <1% of AD cases (74). The vast majority of AD cases are SAD, with the strongest known risk factor being Apolipoprotein E allele (ApoE). ApoE has multiple isoforms with the E2 being neuroprotective and E4 being a risk factor for AD (74). ApoE aids in the degradation of amyloid beta within microglial cells, and the ability of astrocytes to clear diffuse Aβ deposits (75-77). Previous studies have also demonstrated retardation of blood brain barrier (BBB) clearance of amyloid-ApoE aggregates compared to free Aβ via redirection of clearance from the LRP1 to the VLDLR, which internalizes Aβ-ApoE complexes more slowly (75). This clearance delay is isoform dependent with the E4 allele clearing more slowly than E3 and E2. This clearance slowdown may contribute to buildup of amyloid structures on blood vessels and explain the increased risk of cerebral amyloid angiopathy (CAA) associated with the E4 allele of ApoE (75).
Trisomy 21 and AD

Due to the location of the APP gene on chromosome 21, there is a strong correlation between AD and trisomy 21 or Down syndrome (DS). Two-thirds of full trisomy 21 translocation patients develop dementia by the age of 60 (78). Interestingly, this association is only present if the APP gene is present on the extra chromosome, granting a third copy of the gene (79, 80). Patients without a third copy of APP will have DS without the increased risk of developing AD, normally associated with it. Furthermore, translocation of a small fragment of chromosome 21 causing duplicate APP copies on a single chromosome cause FAD but not DS (69, 81). The relationship between an extra copy of APP and AD is strong evidence in support of Aβ as the causative agent in AD.

The Role of Tau in AD

One of the hallmarks of AD is the presence of intracellular aggregates composed of highly phosphorylated tau. Tau is a protein involved in the stabilization of microtubules (5). Tau has multiple phosphorylation sites, and increased phosphorylation levels has an inhibitory effect on microtubule binding leading to a corresponding increase of soluble tau (82, 83). Phosphorylated tau has been shown to closely interact with F-actin causing bundling and aggregation of F-actin forming actin rich rods (84). F-actin is present at the dendritic synapse making tau mediated F-actin aggregation a possible mechanism of synaptic loss in AD (85). The presence of NFTs is
linked to a reduction in expression of synaptic vesicle transport proteins. Levels of soluble tau correlate with AD implicating soluble tau as the neurotoxic form of tau (83, 86, 87). Aβ has been shown to cause dendritic spine loss in the absence of tau; however, neuronal death was tau dependent (88).

Excitotoxicity has been implicated as a mechanism of neuronal death involved in AD (89, 90). Knockout of tau has been shown to attenuate hyper-excitability in mouse models overexpressing Aβ (91). Strong evidence suggests that tau and Aβ act in concert in AD to cause synaptic loss and neuronal death (43, 45, 86, 92, 93). However, in the front cortex of AD patients, Aβ levels were found to be increased prior to the onset of significant tau pathology (94). Additionally, reduction in soluble Aβ levels has been linked to a decrease in tau accumulation. Increased levels of Aβ peptides have also been linked to the phosphorylation of tau (82, 93, 95, 96). Aβ dimers isolated from AD brains induce phosphorylation of tau causing neuritic degeneration (97). This evidence suggests that although a strong link between tau and AD exists, tau phosphorylation and aggregation is likely a downstream effect of Aβ buildup. This supports the case that although tau is intimately linked to AD, buildup of Aβ peptide is likely the initiating factor in AD pathogenesis.
Aβ Structural Studies

Consistent with the majority of transmembrane proteins, the amyloid beta segment of the APP is α-helical prior to cleavage and exit from the lipid membrane. Supporting this is data from NMR studies on a segment of the APP containing the Aβ sequence embedded in micelles which show the Aβ sequence to form an α-helix with a disordered C-terminus (98, 99). Structural changes and aggregation commences once the hydrophobic Aβ peptides enter an aqueous environment.

Amyloid Beta Fibrils

Both solid-state nuclear magnetic resonance (ssNMR) and X-ray diffraction have shown mature amyloid fibrils to possess a cross β-structure; meaning the β-sheet plane and backbone hydrogen bonds connecting β-strands are parallel to the main fibril axis while the β-strands run perpendicular to the fibrillar axis (100, 101). Recently, studies have shown the presence of steric zippers in amyloid fibrils (102, 103). Steric-zippers are formed by the C-terminus of pairs of cross β-sheets with interdigitating side chains (102, 103). TEM studies have shown mature fibrils to contain one or more protofilaments and to display two-fold symmetry with the fibril cross section superimposing with itself after 180 degree rotation (104-106).

Studies indicate that amyloid fibrils, formed by both the Aβ1-40 and Aβ1-42, are composed of in-register parallel β-sheets (107-109). However, fibrils formed by the Iowa mutant Aβ peptide can have either parallel or antiparallel architecture (110). Aβ fibrils and oligomers are polymorphic
with their internal structure often changing in an environment dependent manner, highlighting the importance of utilizing relevant experimental conditions (108). Fibrils seeded by brain extracts of AD patients had different structures, indicating that different seeds can induce formation of distinct fibrils and that fibril structure is not necessarily consistent between patients (107). Aβ samples often show intra-sample polymorphism; meaning that measurements such as NMR and CD demonstrate the average and/or most prevalent of the multiple different structures within a sample (108). The polymorphic nature of Aβ aggregates complicates the reproducibility of Aβ structural data.

Oligomeric Amyloid Beta

The toxicity of Aβ oligomers is linked to both oligomer size and structure. Dodecamers of Aβ isolated from the brains of Tg2576 mice disrupted the memory of young rats (111). While Aβ dimers isolated from the cerebral cortex of AD brains inhibited LPT in rat hippocampal slices and impaired memory when injected into rats (112), Aβ dimers, trimers, and tetramers were found to inhibit LTP in mouse hippocampal neurons at physiological concentrations, with trimers having the greatest effect (38). Ion mobility, coupled with mass spectroscopy experiments, found that Aβ1-40 monomers form dimers, which then dimerize, and then likely undergo fibrillogenesis while Aβ1-42 tetramers went on to form hexamers, and then dodecamers (113).
It is commonly believed that the toxic species of Aβ are oligomers of mixed α-helix/β-sheet content formed during the transition from α-helical monomer to cross β-sheet fibril (114-116). The transient nature of these aggregates makes their study difficult, therefore structural data on oligomeric Aβ is lacking. Studies that have been conducted on the oligomeric Aβ have found presence of both parallel and antiparallel β-sheet, along with mixed α/β structures (117-122). One group demonstrated that inhibiting the formation of antiparallel β-sheet led to a corresponding decline in toxicity (119). Many studies have used non-physiological conditions in order to stabilize these oligomers, calling into question the physiological relevance of their findings (49, 66, 115, 116, 123).

Aβ Aggregation

Protein fibrillization is implicated in multiple human diseases including AD, Parkinson’s disease, and Huntington’s disease. Fibrillization takes place in three stages: a lag phase during which prefibrillar intermediates are formed, a growth phase of rapid fibril growth and elongation, and finally growth plateaus once fibrillogenesis reaches equilibrium (124, 125). Aβ fibrillization takes place via nucleated growth with the C-terminus being critical in the seeding of fibrillization (126-129). The rate of fibrillogenesis is dependent on both pH and temperature (130, 131). Studies have indicated that formation of a turn at residues ~23-28 is critical to Aβ fibrillization and toxicity. This sequence is home to multiple mutations that lead to FAD, indicating the importance of this
turn to the disease state (132). Structural studies indicate that this turn is part of a β-hairpin structure formed as an intermediate during aggregation (114, 133). Previous studies have found AβpE3-42 to aggregate faster than, and have a higher β-sheet propensity than Aβ1-42, likely due to increased hydrophobicity (125, 134). Conversely, other studies have found that AβpE3-42 aggregates slower and has lower β-sheet propensity (135). Additionally, it was found that AβpE3-42 increased the lag phase of Aβ1-42 and delayed β-sheet formation (135). Further studies are needed to clarify fibrillization kinetics of Aβ1-42 and AβpE3-42 as well as the effect AβpE3-42 has on Aβ1-42 fibrillogenesis.

**Cell Death in AD**

There have been many proposed mechanisms of Aβ mediated cytotoxicity. Many different mechanisms have been demonstrated in vitro, but more study is needed to ascertain their relationship to the disease in vivo. These mechanisms include the alteration of mitochondrial dynamics, loss of calcium homeostasis, and trans-nitrosylation of proteins due to increased RNS production.
Alteration of Mitochondrial Dynamics

Mitochondrial dynamics, or their constant fission and fusion, is used to dilute mitochondrial DNA damage and maintain a healthy mitochondria population (136). Alterations in mitochondrial dynamics has been implicated as a mechanism of both synaptic degradation and neuronal death in AD. Neurons are highly energy dependent due to the large energy exertion required to maintain synapses, as well as the re-uptake and release of neurotransmitters. Aged mitochondria display reduced activity of complex I and IV in the respiration chain (137). Mitochondrial DNA mutations accumulate over time due to oxidative species formed during respiration (138). Fractionated mitochondria and broken cristae have been found in AD brains, indicating a loss of mitochondrial dynamics homeostasis (139). Fragmented mitochondria produce less ATP production and more reactive oxidative species (ROS) (136). Oxidative damage has been described in lipid membranes and proteins in AD brains, providing evidence for the role altered mitochondrial dynamics play in the disease (139, 140). Increases in mitochondrial derived ROS have been linked to upregulation of APP increasing Aβ levels in a positive feedback mechanism (141). Increased ROS production is also an early signal of apoptosis (142). Fusion of mitochondria is carried out via a complex of mitofusins 1 and 2 and optic atrophy 1 (136, 143). Mitochondrial fission is carried out via dynamin-related protein 1 (drp1), which is targeted to the mitochondrial outer membrane via: mitochondrial fission factor mitochondrial fission protein 1 and, mitochondrial elongation factor 1 (136). Up-regulation of mitochondrial fission in AD is believed to be due to increased activity or localization of drp1 due to post-translational modification, although the exact mechanism is controversial. Some groups have theorized that this occurs
through increased GTPase activity of Drp1 via nitrosylation (144, 145). Other groups argue that the altered dynamics is due to increased targeting of drp1 to mitochondria due to phosphorylation of drp1 (146). Additionally, enhanced levels of glycogen synthase kinase 3β (GSK3β) have been found in AD patients (96). GSK3β has been linked to phosphorylation of drp1 upregulating its activity, as well as an increase in Cdk5 activity and tau expression (95, 147).

Loss of Calcium Homeostasis

Loss of intracellular calcium homeostasis is also implicated in AD neuronal death. Calcium is a vital intracellular signaling molecular responsible for regulating many signal cascades. Loss of calcium homeostasis has been linked to cellular apoptosis (148). Studies have shown Aβ peptides to cause deregulation of calcium homeostasis, providing evidence for it being a mechanism of cellular death in AD (149-155).

There have been many proposed pathways that Aβ affect calcium regulation. Aβ peptides have been linked to the upregulation of ryanodine receptors, specifically Ryanodine Receptor 3 (RyR3) (153-155). These receptors release calcium from the endoplasmic reticulum (ER) in response to increases in intracellular calcium termed calcium induced calcium release (CICR). Increased levels of tau and Aβ are linked to increased glutamate levels through increased expression and inhibition of re-uptake and transport (156-159). Glutamate can activate both RyR3 and NMDAR increasing intracellular calcium. Soluble Aβ oligomers were found to have high
affinity for PrP\textsuperscript{c}. These complexes were found to interact with a complex of mGluR5 and Fyn, causing increased NMDAR activity and thus calcium influx (160). It was also found that these Aβ-PrP\textsuperscript{c}-mGluR5 complexes mediate dendritic spine loss through eEF2 phosphorylation. Additionally, Aβ peptides have been shown to inhibit the activity of mGlu7 an NMDAR regulator further increasing NMDAR activation and subsequence calcium influx. Increases in intracellular Ca\textsuperscript{2+} concentrations mediates signaling changes via multiple mechanisms. In response to increased calcium the calcium dependent protease calpain cleaves the Cyclin dependent kinase 5 (Cdk5) activators p35 to p25 or p39 to p29, causing aberrant increased Cdk5 activity (161, 162). This increased Cdk5 activity has been demonstrated to lead to an increase in Aβ production as well as production and hyper-phosphorylation of tau (95, 161, 162).

Amyloid Pore Formation

Another mechanism of loss of calcium homeostasis in AD is the formation of calcium permeable channels composed of Aβ in the organelles and plasma membranes of neurons (121, 149, 163-167). These pores have been observed in AD brains and in vitro assays have demonstrated an influx of calcium through Aβ pores at physiological peptide concentrations, lending credence to this theory (163, 164, 167). Evidence shows that Aβ behaves similarly to gramicidin, an antimicrobial agent which has mostly β-sheet structure and forms pores in plasma membranes (168). Additionally, the Aβ oligomer conformation specific antibody A11 binds
selectively to the bacterial pore forming protein αHL as well as human perforin, indicating shared homology and possibly similar mechanisms of pore formation (169). A close link was found for both Aβ1-42 and Aβ1-40 between pore formation and cytotoxicity (121). Structural studies indicate that these pores may consist of β-barrel like structures composed of monomers of Aβ in either parallel or antiparallel β-sheet (170, 171). Other MD simulations on short Aβ peptides predict octameric pores composed of mostly α-helical structure (172).

Nitrosylation of Proteins in AD

Excess levels of nitric oxide (NO) leading to increased S-nitrosylation (SNO) of proteins has been linked to AD (173). NO is produced by nitric oxide synthases (NOS) by the conversion of L-arginine to L-citrulline, it easily defuses through plasma membranes allowing it to signal neighboring cells. The two NOS relevant to AD are neuronal nitric oxide synthase (nNOS) and inducible nitric oxide synthase (iNOS). nNOS is found in neurons and is constitutively active, producing low levels of NO. iNOS is constitutively inactive, and when activated, produces high levels of NO. Excessive NMDAR activation in AD has been shown to lead to increased levels of ROS and NO through nNOS activation (174). Additionally, tangle-bearing neurons in the AD brain have been shown to have activated iNOS (175). SNO is a post-translational modification wherein a nitric oxide species undergoes a redox reaction with a thiol group on a cysteine (176). Increasing SNO of proteins has been linked to multiple neurodegenerative diseases, including AD and Parkinson’s disease (144, 145, 161, 177, 178). High levels of SNO proteins has a pro apoptotic
affect (179). Transnitrosylation via S-nitrosylating proteins has been identified as a major mechanism in the proliferation of SNO proteins throughout cells. Numerous proteins have been identified as having the ability to transnitrosylate other proteins including GAPDH, Cdk5, and caspase 3 (176, 180). Cdk5 has been shown to be S-nitrosylated at amino acids 83 and 157 via interaction with iNOS (181). SNO-Cdk5 can act in several neurotoxic mechanisms, including Transnitrosylation of drp1, activation of the pro apoptotic protein ATM, and phosphorylation and loss of function of WAVE1 (180, 182, 183). SNO-Cdk5 has been shown to transnitrosylate Drp1, enhancing its GTPase activity leading to altered mitochondrial dynamics (144, 145, 180, 181). SNO-GAPDH has been found in AD brains; SNO-GAPDH binds Siah1 and translocates to the nucleus where it initiates apoptosis (178, 184, 185). There is also evidence that NO causes cyclin dependent kinase 1 (Cdk1) mediated phosphorylation of drp1 enhancing GTPase activity and mitochondrial fission (146).

The nature of AD, namely the long time scale and the difficulty of studying neurons both in vivo and in vitro, make pin-pointing of a single mechanism of neuronal death difficult. It is likely that some of the aforementioned mechanisms of cytotoxicity are downstream consequences of AD and not direct causes; however, it is reasonable to assume that there are multiple often interconnected neurotoxic pathways in AD. The lack of a single mechanism to target complicates drug development in AD. A stronger understanding of the relationship between Aβ structure and toxicity may pave the way the development of early diagnostic tests for AD or novel structure based AD drugs.
Methodology Literature Search

The polymorphic nature of the Aβ peptide required detailed review of existing literature. To ensure that consistent and reproducible results are obtained, it was necessary to use uniform, monomeric solutions of Aβ in each experiment. Fluorinated alcohols such as 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) are commonly used to induce α-helical structure and monomerization in Aβ peptides (186, 187). In this work, protein secondary structure was determined by CD, literature was therefore reviewed in order to interpret CD spectra (188).

Review of FTIR

Due to the importance of FTIR spectroscopy in this work a thorough review of current literature on FTIR was conducted. Infrared spectroscopy is also called vibrational spectroscopy; absorption of light is associated with various vibrational modes of chemical groups within a molecule. Polychromatic infrared radiation is passed through the sample, when the frequency of infrared radiation matches the vibrational frequency of chemical bonds present in the sample, absorbance occurs. The absorption frequency of FTIR spectra is displayed in wavenumbers where wavenumber \( W = \frac{1}{\lambda} = \frac{\nu}{c} \); where \( \lambda \) is wavelength, \( \nu \) is temporal frequency of vibration, and \( c \) is the speed of light. The vibrational frequency \( \nu \) for a diatomic molecule can be approximated using equation 1; where the spring constant \( k \) is proportional to chemical bond strength.
\[ V = \frac{1}{2\pi} \sqrt{k \left( \frac{1}{m_1} + \frac{1}{m_2} \right)} \]  

(1)

There are many vibrational modes that can be observed in FTIR, but the two most relevant to biological study are the amide I and amide II. The amide I vibrational mode is located 1700-1600 cm\(^{-1}\) and is primarily generated by C=O stretching vibration. These vibrations are coupled through covalent bonding, H-bonding, and through space, these couplings shift vibrational frequency. Protein secondary structure geometry is highly conserved, making the C=O vibrational frequencies of various secondary structures also highly conserved. This allows accurate attribution of an FTIR absorbance band to a specific secondary structure. Research was conducted on the locations of these amide I secondary structure absorbance peaks in order to interpret experimental results (189-191). The peak wavenumber and extinction coefficient of various protein secondary structures can be found in chart 1. The amide II is located 1570-1540 cm\(^{-1}\) and is primarily composed of NH in-plane bending. The amide II can be utilized to measure the solvent accessibility of the protein. Amide hydrogen-deuterium exchange will take place with the addition of D\(_2\)O based buffer. The increased mass of deuterium causes a downshift in absorption and corresponding loss of absorbance 1570-1540 cm\(^{-1}\). Proteins in more open or solvent accessible conformations will undergo more H-D exchange and thus lose amide II signal intensity more quickly than tightly packed proteins.
\[ \frac{\frac{1}{13} + \frac{1}{16}}{\frac{1}{12} + \frac{1}{16}} = \sim 0.978 \]
Table 1. Characteristic amide I wavenumber relative extinction coefficients, and integrated absorbance extinction coefficients (B) of various protein secondary structures in D$_2$O, integrated extinction coefficient come from (193).

<table>
<thead>
<tr>
<th>Secondary Structure</th>
<th>Absorbance D$_2$O (cm$^{-1}$)</th>
<th>Relative Integrated Extinction Coefficient</th>
<th>B (M$^{-1}$cm$^{-2}$)</th>
</tr>
</thead>
<tbody>
<tr>
<td>α-helix</td>
<td>1655-1638</td>
<td>1</td>
<td>5.1 x10$^7$</td>
</tr>
<tr>
<td>Parallel β-sheet (Intramolecular)</td>
<td>1636-1630</td>
<td>1.37</td>
<td>7.0x10$^7$</td>
</tr>
<tr>
<td>Anti-Parallel β-sheet (Strong)</td>
<td>1636-1630</td>
<td>1.37</td>
<td>7.0x10$^7$</td>
</tr>
<tr>
<td></td>
<td>1680-1670 (Weak)</td>
<td>Multiply large component by 1.07</td>
<td>(7% of Strong Component)</td>
</tr>
<tr>
<td>Intermolecular (cross-β) β-sheet</td>
<td>1625-1613</td>
<td>1.37</td>
<td>7.0x10$^7$</td>
</tr>
<tr>
<td>β-turns</td>
<td>1675-1640</td>
<td>1.08</td>
<td>5.5x10$^7$</td>
</tr>
<tr>
<td>Unordered Structure</td>
<td>1648-1640</td>
<td>0.88</td>
<td>4.5x10$^7$</td>
</tr>
</tbody>
</table>
CHAPTER THREE: METHODOLOGY

In this project, we examined Aβ1-42, AβpE3-42, and combined samples at both equimolar and 9:1 (Aβ1-42:AβpE3-42) ratios. These molar ratios were utilized because AβpE has been observed in AD brains at up to 50% of total soluble Aβ load but is commonly present at a lower ratio (13, 20, 22). However, it has also been demonstrated to have a profound affect even at low molar ratios (44, 194). The secondary structures of early oligomers and intermediate structures were determined utilizing FTIR and CD. Peptides were first dissolved at concentrations of either 200 or 50 μM in HFIP to break up pre-formed aggregates. Monomer formation of the peptides was confirmed by the formation of α-helix in HFIP (187). The removal of HFIP was conducted by streaming N₂ gas over the samples until dried then vacuum desiccating samples for 15 minutes.

Bulk aqueous buffer was then added to the dried samples. Two different buffers were used one at near-physiological ionic concentration and one with low ionic content. The near-physiological buffer was 50 mM phosphate buffer + 50 mM NaCl pH 7.2 (pD 6.8 for FTIR samples in D₂O buffer) and the buffer of low ionic content was 10 mM phosphate pH 7.2 (pD 6.8 for FTIR samples in D₂O buffer). Buffer was added to produce a final peptide concentration of 50 μM. The AβpE3-42 is missing 3 N-terminal charges compared to the unmodified Aβ. It is likely these charges form ionic bonds stabilizing the peptides, increasing ionic pressure will weaken these bonds and can cause changes in structure distribution. Examining structural changes of the peptides in both conditions provides information on the structure formed by the N-terminus of the peptide.
Cytotoxicity Assays

Cytotoxicity assays were conducted with collaboration with Dr. Lucia Cilenti in the laboratory of Dr. Kenneth Teter. To assay the cytotoxicity of Aβ aggregates, PC12 cells were grown in RPMI 1640 media, supplemented 10% fetal bovine serum, 50-units/ml penicillin and 50 μg/ml streptomycin. For MTS viability assays cells were seeded in 96-well plates in triplicate/samples at a density of 10,000 cells/well in 100 μL complete medium for 18 hours. Following this, 100 μL of fresh medium containing Aβ samples aggregated for 2, 4 and 24 hours by stirring at 37 °C in PBS, was added to cells followed by incubation at 37 °C for 28 and 50 hours. Cell viability was determined by MTS assay, a cell proliferation assay, to monitor methanethiosulfonate tetrazolium reduction as an estimate of cell viability, according to the manufacturer’s instructions (Promega). In the assay, 20μl of MTS tetrazolium substrate solution was added to the wells at 28 and 50 hours followed by further incubation at 37 °C for 3 hours, Cell viability in each well was assayed by reading the absorbance at 590 nm in a BioTek microplate reader Synergy 2. Percentage of cell viability was calculated by subtracting the average of the triplicate samples at 490nm absorbance from medium control (no cells/background) from all other absorbance values.
Membrane Calcium Release

The ability of Aβ aggregates to induce the release of calcium from lipid vesicles was assayed using Quin-2. 40 μM Quin-2 in the presence of 100 nm unilamellar vesicles of POPC/POPG/cholesterol (6:3:1) loaded with 30 mM CaCl₂ in aqueous buffer pH 7.2. The total lipid concentration was 0.5 mM and peptides were added for a final ratio 1:100 peptide:lipid. Peptides were added after 2 and 24 hours of aggregation at 37 °C in PBS. Control was conducted by addition of PBS followed by complete release of all entrapped Ca²⁺ via addition of 0.05% Triton X-100 which disrupted vesicles.

FTIR

All FTIR measurements were taken on a Vector-22 FTIR spectrometer (Bruker Optics, Billerica, MA, USA) equipped with a liquid N₂ cooled Hg-Cd-Te detector with a 2 cm⁻¹ resolution. All buffers were made utilizing D₂O, and not H₂O, to avoid artifacts caused by absorption of H₂O in the amide I region. Transmission spectra collected for all samples were taken by co-adding either 500 or 1000 consecutive scans. Peptides dissolved in HFIP were first deposited on the CaF₂ FTIR window, and then desiccated for 15 minutes to remove HFIP. Transmission spectra were then taken and absorption was calculated using a reference transmission spectra. After the collection of a dried sample, buffer was added along with a second CaF₂ window. Separating CaF₂ windows was a 50 μm Teflon spacer. Transmission spectra were then taken consecutively and
absorbance was calculated using a buffer reference. Data for both uniformly and segmentally $^{13}$C labelled peptides was obtained similarly along with data for mixed samples. Samples of atmospheric vapor was collected separately and used to clean up spectra as necessary. Spectra were smoothed using a 13-point Savitzky-Golay linear least squares algorithm and then baselined. Absorbance spectra were prepared using OPUS spectroscopy software.

**Curve-Fitting of FTIR Spectra**

Curve-fitting of FTIR spectra was performed using GRAMS IO spectroscopy software. The locations of amide I components were based on negative peaks in the second derivative. Curve-fitting was considered acceptable when peak wavenumbers of components were in agreement with the second derivatives, the sum of all components reasonably fit the experimental spectra, and the peak component widths were within reasonable limits i.e. width at half height of less than 40 wavenumbers (190). The relative fraction $F_i$ of either $\alpha$-helix ($\alpha$), $\beta$-sheet ($\beta$), $\beta$-turn (t), and other structures, were calculated based on the area of fit peaks using equation 3 where $B$ refers to the average integrated extinction coefficient of the described structures as previously described (195).

$$F_i = \frac{a_i}{B_i (\frac{a_\alpha}{B_\alpha} + \frac{a_\beta}{B_\beta} + \frac{a_t}{B_t} + \frac{a_{other}}{B_{other}})}$$  \hspace{1cm} (3)
Hydration FTIR

To facilitate examination of early peptide intermediates and structural transformations peptide transition was delayed by hydrating from gas phase, using D\textsubscript{2}O vapor and not aqueous buffer. This was done using two separate mechanisms. In the first, dried peptides both individually and in combination, were hydrated via exposure to ambient humidity. For the second a custom apparatus was designed to hydrate peptides inside the FTIR spectrometer via the pumping in of D\textsubscript{2}O laden N\textsubscript{2} gas (Figure 1). In this setup two separate hoses of N\textsubscript{2} gas was bubbled through two flasks of D\textsubscript{2}O and then piped into the spectrometer. Peptides were prepared from 50 \(\mu\)M stocks in HFIP as described earlier. To examine the effect of co-incubation peptides were dried on either the same side or opposite sides of the CaF\textsubscript{2} windows to allow comparison between interacting and non-interacting peptides (Figure 1A).

Figure 2. A) Schematic depiction of the experimental set-up. Nitrogen gas is pumped through simmering D\textsubscript{2}O into the sample compartment. Only two of four flasks with D\textsubscript{2}O are shown for simplicity. Two sample holders are mounted vertically, at 90 degrees, one with two peptides at opposite sides of a CaF\textsubscript{2} window and one with both peptides blended at one side. Consecutive FTIR spectra of the two samples are measured while the sample holder frame is turned back and forth by 90 degrees. Red arrows represent the infrared light. B) Photograph of the FTIR spectrometer during an actual experiment. The inset (middle bottom) provides a glimpse into the sample compartment.
Circular Dichroism

CD measurements of Aβ in HFIP were taken in either a 0.5 mm cylindrical cuvette or a 4x4 mm rectangular quartz cuvette. Measurements were conducted on a Jasco J-810 spectropolarimeter (Tokyo, Japan). For measurements in aqueous buffer HFIP was removed with N₂ gas followed by desiccation for 30 minutes, prior to the addition of buffer. After the addition of 50 mM phosphate + 50 mM NaCl pH 7.2 aqueous buffer samples were incubated at 37°C while stirring and a final protein concentration of 50 μM. CD measurements were taken between 330-180 nm. After collection spectra were smoothed in Spectra Manager software using 9 point Savitzky-Golay linear least squares algorithm.

TEM

TEM measurements were performed with the assistance of the lab of Dr. Bo Chen (University of Central Florida, Orlando, FL, USA). Peptides were dissolved in HFIP, dried, and buffer was added as previously described. Samples were then stirred at 37°C for 24 hours. For measurements 5 mL of sample was placed on graphene coated grids. After five minutes excess buffer was removed. Samples were then washed twice with diH₂O and negatively stained with 3% uranyl acetate. Samples were measured on a JEOL TEM-1011 (Tokyo, Japan) at 80kV. Samples were examined at 2,4,12, and 24 hours to examine aggregation and morphology.
CHAPTER FOUR: RESULTS

Pyroglutamylated Amyloid-β Peptide Reverses Cross β-Sheets by a Prion-Like Mechanism

Circular Dichroism of Aβ Proteins

We first sought to clear up disagreement in the literature about the β-sheet propensity of AβpE compared to the unmodified peptide. Some groups reported AβpE to have a lower β-sheet propensity than the unmodified peptide while others have proposed the opposite. To clear up this contradiction we examined the structural changes of AβpE and unmodified Aβ throughout aggregation using CD.

To prepare monomeric samples Aβ was first dissolved in HFIP to break up pre-formed aggregates. HFIP disrupts β-sheet formation and promotes formation of α-helical structure (187). CD spectra of peptides dissolved in HFIP at 50 μM show a minima at 203 with a shoulder at 220 nm (Figure 3A). This is indicative of α-helix and disordered structures. This is in agreement with previous data of Aβ proteins in HFIP and implies a monomeric solution. Spectra taken after the removal of HFIP indicate that the peptides are α-helical shown by two minima located at 208-209 nm and 221-224 nm (Figure 3B). Interestingly, the AβpE3-42 has a significantly reduced θ208/θ222 ratio, indicating a more flexible or disordered α-helix (196).
Figure 3. (A) CD spectra of Aβ₁₋₄₂ (red), Aβₚₑ₃₋₄₂ (blue) their 9:1 (teal) and, equimolar (green) ratios in HFIP at a peptide concentration of 50 μM. (B) CD spectra of the same peptides following HFIP removal via N₂ drying and vacuum desiccation.

Following desiccation aqueous buffer was added to the sample for a final peptide concentration of 50 μM and samples were constantly stirred at 37°C. In physiological buffer conditions Aβ₁₋₄₂ rapidly forms β-sheet as shown by the broad minima at 216-219 nm present 10 minutes after the addition of buffer (Figure 4A). After 16 hours this minima had red shifted to 220 nm possibly indicating decreased accessibility of the solvent due to tight packing during aggregation, such as in fibrillogenesis. Alternatively, Aβₚₑ₃₋₄₂ spectra at 10 minutes has a wide minima from 208-230 nm likely indicating presence of α-helical, β-sheet, and turn structures (Figure 4B). After 2 hours this minima has shrunk to 212-223 nm indicating the presence of a combination of both α-helical and β-sheet structures. After 24 hours of aggregation a single minima at 219 nm is present indicating a majority β-sheet structure. This demonstrates that Aβ₁₋₄₂
readily forms β-sheets while Aβ<sub>pE3-42</sub> has a higher propensity to retain α-helical structure and delayed formation of β-sheet.

The 9:1 (Aβ<sub>1-42</sub>:Aβ<sub>pE3-42</sub>) combination after 10 minutes of aggregation contains a wide minima at 217 nm consistent with the presence of mostly β-sheet (Figure 4C). Throughout aggregation this peak grows in intensity, after 24 hours a single minima at 219 nm is present indicating the likely presence of fibrils. For the first hour the equimolar combination contains mixed α-helix/β-sheet content indicated by the wide minima 210-216 at ten minutes and two minima at 212 and 222 nm after one hour (188). At 2 hours of aggregation onward a minima located at 217 nm indicates presence of mostly β-sheet structure. The equimolar combination after one hour resembles the Aβ<sub>pE3-42</sub> in that it retains α-helical structure and resists converting fully to β-sheet structure (Figure 4D).

This data indicates that AβpE has a lower β-sheet propensity than unmodified Aβ. Data from combined samples indicates that Aβ<sub>pE3-42</sub> alters Aβ<sub>1-42</sub> structural transition. Alone, Aβ<sub>1-42</sub> rapidly forms fully β-sheet aggregates, while forming mixed α-helix/β-sheet aggregates in equimolar combination with Aβ<sub>pE3-42</sub>. 
Figure 4. CD spectra of Aβ1-42 (A), AβpE3-42 (B), their 9:1 (Aβ1-42/AβpE3-42) (C) and, equimolar (D) ratios in 50 mM phosphate 50 mM NaCl buffer pH 7.2 Spectra are shown 10 minutes (red), 1 hour (green), 2 hours (blue) and, 24 hours (pink) after addition of buffer. Final peptide concentration was 50 µM and aggregation took place at 37°C with constant stirring. For Aβ1-42 the spectra in pink corresponds to 17h as subsequent time points gave weak signal due to evaporation of the sample. Spectra were cut at 210 nm due to weak signal from Cl and peptide absorbance.

TEM of Aβ Fibrils

Secondary structure is linked to fibrillogensis and fibril morphology (134). The structural differences between the two peptides therefore indicate a strong possibility of altered fibrillogensis. There are currently disagreements in the literature about the fibrillization kinetics of AβpE in comparison to the unmodified peptides. To clear this up, fibril formation and morphology was examined via TEM. Samples were examined at 2,4,12, and 24 hours of aggregation in 50 mM phosphate + 50 mM NaCl buffer pH 7.2. To determine the effect of peptide interaction peptides were examined separately as well as in equimolar and 9:1 (Aβ1-42:AβpE3-42) mixed samples.

The largest differences between samples was observed after 2 hours of incubation. The AβpE3-42 sample is dominated by irregularly shaped prefibrillar aggregates with dimensions
between 30-100 nm (Figure 5b). The Aβ₁₋₄₂ sample at 2 hours consists mostly of fibrils with a smaller number of pre fibrillar aggregates (Figure 5a). The rapid formation of pre-fibrillar aggregates by AβₚE₃₋₄₂ may be due to its increased hydrophobicity. Both the 9:1 (Figure 5c) and 1:1 (Figure 5d) samples resemble the AβₚE₃₋₄₂ sample with a large number of pre-fibrillar aggregates compared to mature fibrils. At 4 hours fibrils were present in all samples along with significant amounts of prefibrillar aggregates (Figure 5e-h). At 12 (Figure 5i-l) and 24 (Figure 5m-p) hours fibrillogenesis continued and more mature fibrils were found in all samples along with decreased levels of prefibrillar aggregates.

This data demonstrates that the unmodified Aβ undergoes more rapid fibrillogenesis than AβₚE. This data agrees with CD data showing that Aβ₁₋₄₂ rapidly forms β-sheet indicative of fibril formation while AβₚE₃₋₄₂ and the 1:1 combination retain a prominent α-helical component. The increased levels of prefibrillar aggregates compared to fibrils at two hours in mixed samples demonstrates that AβₚE₃₋₄₂ has a profound effect on fibrillogenesis particularly in the early stages of aggregation (135). The lack of fibrils in the 9:1 sample is evidence of the strong effect AβₚE₃₋₄₂ can exert even at low molar ratios. Interestingly, in the 9:1 sample there was no delay in β-sheet formation coinciding with the delay in fibrillogenesis. This indicates that the delay in fibrillogenesis found in mixed samples may not simply be due to inhibition of β-sheet formation.
FTIR of Amyloid Beta Peptides

We next sought to examine the structure of these peptides in greater detail utilizing FTIR. FTIR gives greater structural resolution than CD allowing, for instance, the determination of whether the protein is forming intramolecular or intermolecular β-sheet. Formation of
intramolecular β-sheet and not intermolecular β-sheet, as found in fibrils, may explain the delay of fibrillogenesis despite rapid β-sheet conversion of the 9:1 sample. Utilizing uniformly $^{13}$C-labeled Aβ$_{1-42}$ allowing the assignment of structural components to individual peptides in mixed samples. This allowed the probing of structural changes in both peptides caused by interaction with one another.

Peptides were first examined individually by depositing 40 μL of a 200 μM solution of Aβ in HFIP to the CaF$_2$ FTIR window. HFIP was then removed via vacuum desiccation for 15 minutes and FTIR measurements were taken of the proteins in a dried state. The $^{13}$CAβ$_{1-42}$ spectra contains a major peak at 1588 cm$^{-1}$ indicating the presence of intermolecular β-sheet structure (Figure 6). It also contains a broad component likely corresponding to β-turns (~1660 cm$^{-1}$) and an insignificant α-helical component (1617 cm$^{-1}$). The Aβ$_{PE3-42}$ is forming intramolecular β-sheet that is possibly anti-parallel as indicated by the peak at 1634 cm$^{-1}$ and small shelf present at 1695 cm$^{-1}$ (189) (Figure 6). The presence of structures other than α-helix in the dry samples indicates that the peptides can undergo structural transitions in the absence of aqueous buffer due to atmospheric humidity.
Figure 6. FTIR spectra of Aβ_{pE3-42} (Light Blue) and uniformly ^13\text{C} labeled Aβ_{1-42} (Green) dried from a 200 μM HFIP solution on a CaF_2 Window. The amide I area of spectra was normalized.

The observation that atmospheric humidity was sufficient to induce structural changes gave us the idea to examine the effect of Aβ_{pE3-42} on the early stages of Aβ_{1-42} aggregation utilizing atmospheric humidity. Using humidity we examined early transitions of both equimolar and 9:1 molar combination samples. Samples in HFIP were added to FTIR windows and HFIP was removed by desiccation as described earlier. Samples were then exposed to atmospheric humidity for either 10 or 20 minutes and FTIR spectra was taken. Individual peptides were also measured after 15 minutes of atmospheric humidification and their weighted sum was compared to combined samples. The absorption of atmospheric humidity is demonstrated by a corresponding increase in absorbance in the H_2O band located 3450-3150 cm^{-1} (Figure 7A). In the 9:1 molar ratio, as the sample is hydrated the structure transitions from α-helix (1617 cm^{-1}) to β-sheet (1592 cm^{-1}) evidenced by an increased 1592/1617 ratio in the 20 minute sample when compared to the 10
minute sample (Figure 7B). The broad peak ~1655 cm\(^{-1}\) likely corresponds to A\(\beta\)\(_{1-42}\) turn structure as well as A\(\beta\)\(_{pE3-42}\) turn and \(\alpha\)-helical structures. The lower absorbance by the weighted sum of individual peptides at 1617 cm\(^{-1}\) indicates less \(\alpha\)-helical content in the A\(\beta\)\(_{1-42}\) in the absence of A\(\beta\)\(_{pE3-42}\). This is evidence that A\(\beta\)\(_{pE3-42}\) restricts \(\alpha\)-helix to \(\beta\)-sheet transition of the A\(\beta\)\(_{1-42}\). The differences in the equimolar samples are even more pronounced. The weighted sum at 15 minutes contains prominent peaks at 1588 and 1634 cm\(^{-1}\) likely corresponding to intermolecular \(\beta\)-sheet of the A\(\beta\)\(_{1-42}\) and intramolecular \(\beta\)-sheet of the A\(\beta\)\(_{pE3-42}\) respectively (Figure 7C). The broad shelf ~1660 cm\(^{-1}\) is likely composed of A\(\beta\)\(_{1-42}\) turns as well as A\(\beta\)\(_{pE3-42}\) \(\alpha\)-helix and turn structures. Experimental spectra at 10 minutes show a decrease in \(\alpha\)-helix-to-\(\beta\)-sheet transition of A\(\beta\)\(_{pE3-42}\) evidenced by a decrease in 1634/1658 ratio when compared to the weighted sum. The A\(\beta\)\(_{1-42}\) \(\alpha\)-helix-to-\(\beta\)-sheet transition is also inhibited at 10 minutes as demonstrated by an increase in peak height at 1617 cm\(^{-1}\) and a decrease in the corresponding \(\beta\)-sheet height present at 1595 cm\(^{-1}\) in the experimental and 1588 cm\(^{-1}\) in weighted sum spectra’s respectively. The peak at 1595 cm\(^{-1}\) likely corresponds to intra- not intermolecular \(\beta\)-sheet structure. At 20 minutes the differences are even more pronounced. The major peak at 1658 cm\(^{-1}\) indicates that A\(\beta\)\(_{pE3-42}\) is mostly \(\alpha\)-helical. Minor shelves located at 1617 and 1595 cm\(^{-1}\) correspond to A\(\beta\)\(_{1-42}\) \(\alpha\)-helix and intramolecular \(\beta\)-sheet respectively. The similar intensities at 1617 cm\(^{-1}\) for both 10 and 20 minutes indicate a lack of transition from \(\alpha\)-helix of the A\(\beta\)\(_{1-42}\).

This data indicates that at 10% of total peptide A\(\beta\)\(_{pE3-42}\) delays formation of cross-\(\beta\) structure of A\(\beta\)\(_{1-42}\). At 50% the effect is even more pronounced with A\(\beta\)\(_{pE3-42}\) inhibiting
intermolecular β-sheet formation of Aβ1-42 in favor of intramolecular at 10 minutes, and inhibiting any β-sheet formation at 20 minutes. Additionally, the Aβ_pE3-42 forms more α-helix than β-sheet when in combination with Aβ1-42, this indicates that Aβ1-42 inhibits Aβ_pE3-42 α-to-β conversion.

Figure 7. FTIR spectra of $\mathrm{A\beta_{pE3-42}}$ and uniformly $^{13}\mathrm{CA\beta_{1-42}}$ at 1:9 molar ratio (A and B) and 1:1 molar ratio (C). Green and Red lines are experimental spectra of a sample prepared in HFIP, followed by solvent removal by desiccation and exposure to atmosphere for 10 and 20 min, respectively. The Blue is the weighted sum of the spectra of each peptide measured individually, exposed to the atmosphere for 15 min. Construction of the weighted sum spectra is described under Figure 4. Panel B is a zoom-in into the amide I/II region of spectra shown in panel A.

We next examined structural differences between the peptides in aqueous buffer, 10 mM phosphate pH 6.8 buffer was added to samples following measurement of the dried peptides and spectra were taken every ten minutes. After the addition of buffer both peptides formed predominantly intermolecular β-sheet structure evidenced by a major peak at 1628 cm$^{-1}$ for the Aβ_pE3-42 (Figure 8B) and 1585 cm$^{-1}$ for the $^{13}\mathrm{CA\beta_{1-42}}$ (Figure 8A). Additionally, the Aβ_pE3-42 had significant turn and α-helical components as evidenced by the secondary peak ~1673 cm$^{-1}$. The small peak at 1673 cm$^{-1}$ in the $^{13}\mathrm{CA\beta_{1-42}}$ sample is likely due to trifluoroacetic acid (TFA) which is commonly found in synthesized peptides.
Examination of the Amide II components of spectra gives additional insight into protein structure. Use of a D$_2$O based buffer causes hydrogen-deuterium (H-D) exchange and a corresponding loss of amide II intensity around 1540 cm$^{-1}$ (190, 197). Examination of the Amide II of both peptides for two hours shows a loss of amide II intensity for the A$\beta_{pE3-42}$ and no loss of intensity for A$\beta_{1-42}$ (Figure 8). The lack of a drop in Amide II intensity indicates that the amide hydrogens are being shielded from the buffer via formation of a more compact tertiary structure and/or a less flexible secondary structure, as is found in mature fibrils.

Figure 8. FTIR spectra of A$\beta_{1-42}$ (A) and A$\beta_{pE3-42}$ (B) in 10 mM Na,K-phosphate in D$_2$O, pD 7.2. Change from Blue to Red corresponds to time of exposure of the peptides to the buffer for 10, 30, 50, 70, 90, and 120 min.

Next, we examined spectra of mixed $^{13}$CA$\beta_{1-42}$ and A$\beta_{pE3-42}$ samples to determine structural effects of co-incubation. After 2 hours of incubation in 10 mM phosphate pD 6.8 experimental spectra were compared to the weighted sum of individual spectra. When compared to the weighted
soms of individual spectra the Aβ₁₋₄₂ β-sheet peak (1585 cm⁻¹) is upshifted by 3 and 10 cm⁻¹ in the 9:1 (Figure 9A) and 1:1 samples (Figure 9B) respectively. The latter shift to 1595 cm⁻¹ implies formation of intra- not inter-molecular β-sheet. The AβₚE₃₋₄₂ β-sheet peak (1626-1628 cm⁻¹) was downshifted compared to individual peptides by 4 cm⁻¹ in the equimolar combination. These shifts are likely due to ¹³C:¹²C coupling and imply strong interactions between the two peptides. It is thus clear that Aβ₁₋₄₂ and AβₚE₃₋₄₂ form hybrid oligomers composed mostly of β-sheets. Curiously, in the 9:1 sample AβₚE₃₋₄₂ is upshifted 10 cm⁻¹ from 1626 to 1636 cm⁻¹ (Figure 4A). This peak can most likely be attributed to intramolecular not intermolecular β-sheet which is characteristic of mature fibrils. This implies that when incubated with Aβ₁₋₄₂ at low molar ratio AβₚE₃₋₄₂ fibrillogenesis may be inhibited.

Figure 9. FTIR spectra of AβₚE₃₋₄₂ and ¹³CAβ₁₋₄₂ combined at 1:9 (A) and 1:1 (B) molar ratios, incubated in a D₂O-based phosphate buffer (pD 7.2) for 2 h, at a total peptide concentration of 100 μM. Red and Blue lines are the experimental spectra obtained on the two peptides combined in one sample and the weighted sums of individual spectra, respectively. The weighted sums were obtained as A = ΣfᵢAi, where fᵢ is the molar fraction and Ai is the absorbance spectrum of each individual peptide measured separately.
This project gave insight into the structural transitions of A\(\beta\)\(_{1-42}\) and A\(\beta\)\(_{pE3-42}\) as well as the structure of early oligomers. It was found that A\(\beta\)\(_{1-42}\) has a greater \(\beta\)-sheet forming propensity than A\(\beta\)\(_{pE3-42}\). Additionally, in hybrid samples A\(\beta\)\(_{pE3-42}\) delays or even reverses formation of cross \(\beta\)-sheet by A\(\beta\)\(_{1-42}\). The effect of A\(\beta\)\(_{pE}\) on fibrillogenesis was demonstrated via TEM data showing mature fibrils in the A\(\beta\)\(_{1-42}\) samples while the A\(\beta\)\(_{pE3-42}\) sample contains mostly prefibrillar aggregates. The hybrid samples resemble the A\(\beta\)\(_{pE3-42}\) indicating a strong effect on fibrillogenesis. FTIR data indicates that A\(\beta\)\(_{pE}\) inhibits formation of A\(\beta\)\(_{1-42}\) intermolecular \(\beta\)-sheet which makes up fibrils. This inhibition of \(\beta\)-sheet formation and thus fibrillization of A\(\beta\)\(_{1-42}\) by A\(\beta\)\(_{pE3-42}\) is interesting and a possible mechanism of increased toxicity. Delay or inhibition of fibrillization likely leads to a corresponding increase in the population of soluble oligomers or drive the formation of off-pathway aggregates of increased toxicity. However, the lack of \(\alpha\)-helical structure in FTIR of dried peptides indicates structural transitions had occurred before buffer addition, calling these results into question. In addition the peptides were examined in buffer with significantly less ionic content that in physiological conditions. Moving forward with this project, we sought to examine the early oligomer structure of A\(\beta\)\(_{pE}\) and unmodified A\(\beta\) as well as address these two concerns.
Isotope-Edited FTIR Reveals Distinct Structural Features of Unmodified and Pyroglutamylated Amyloid-β Peptides During Oligomerization

Next, we sought to characterize the structure of oligomers formed by Aβ₁₋₄₂ and AβₚE₃₋₄₂ as well as hybrid oligomers (198). In mixed samples it was observed that AβₚE₃₋₄₂ inhibits cross β-sheet formation and fibrillogenesis of Aβ₁₋₄₂. Aβ oligomers are heavily implicated in AD but little is known of their structures, so we wished to better characterize the structure of the oligomers formed by these peptides. Here we utilized peptides ¹³C- and ¹⁵N-labeled at specific stretches, these labels allow site specific determination of secondary structure as well as provide tertiary and quaternary structural information. Labeled proteins were examined in both 10 mM phosphate buffer pD 6.8 as well as in near-physiological 50 mM phosphate + 50 mM NaCl buffer pD 6.8. These data provide structural constraints for the modeling of early monomers and oligomers of Aβ. Using these constraints, we propose a possible structure for monomeric Aβ as well as likely mechanisms of early oligomerization.

Isotope Labeling of Peptides

In order to gain site-specific secondary structural information we utilized peptides that had been ¹³C and ¹⁵N labelled at specific locations. Peptides were generated with labels in two locations, K¹⁶L¹⁷V¹⁸ and V³⁶G³⁷G³⁸V³⁹. Solution NMR studies of the Aβ containing APP segment reconstituted in micelles show an α-helix starting at K¹⁶L¹⁷V¹⁸ and a bend involving V³⁶G³⁷G³⁸V³⁹ near the C-terminus. After cleavage of Aβ from the membrane this α-helical structure undergoes
structural transitions eventually forming the cross β-sheet structure found in fibrils. The $^{13}$C labelling of these segments causes a downshift in the amide I spectra allowing site-specific secondary structural information. In addition by examining the carbon coupling of these labelled segments we are able to gain quaternary structural information. If two labelled segments are in close proximity as is found in the in-register parallel β-sheet characteristic of fibrils they will undergo $^{13}$C:$^{13}$C coupling and a further downshift of absorbance will occur. If the labelled segments are not in close proximity to one another they will instead undergo $^{13}$C:$^{12}$C coupling and a slight upshift of their associated absorbance peak will occur.

**FTIR of Dried Proteins**

Prior to the addition of buffer, measurements were taken of the peptides dried from HFIP. Peptides in HFIP were first deposited on the CaF$_2$ window and then HFIP was removed via desiccation. It was previously observed that atmospheric humidity is sufficient to induce structural changes. In order to obtain reliable data, HFIP is used break up pre-formed aggregates and monomerize Aβ. Previously, in CD of proteins dried from HFIP we observed α-helical structures. We sought to capture this α-helical structure in FTIR to ensure consistent Aβ populations prior to the addition of bulk aqueous buffer. To ensure this, we lowered the protein concentration to 50 µM in HFIP, as high concentrations have been shown to induce aggregation (199). When peptides were dried from HFIP, using the lower concentration and keeping care not to keep samples in the
humid lab air for long, both Aβ₉-E₃-42 and Aβ₁-42 as well as their equimolar combination form mostly α-helical structure, evidenced by the absorption peak at 1658-1662 cm⁻¹ (Figure 10A). This absorbance is higher than is found in more stable α-helices (1647-1657 cm⁻¹) and suggests that the α-helix formed by Aβ peptides is more flexible. This more flexible α-helix agrees with previous data of the Aβ₁-42 segment of the APP (98, 99). To accurately place and quantify the additional peak generated by the labeled residues the second derivative of dried spectra was calculated (Figure 10B). Peak fitting was then performed to quantify the additional peaks (Table 2) (Appendix A). For K¹⁶L¹⁷V¹⁸ labeled peptides an additional peak at 1624-1628 cm⁻¹ is found corresponding to the labelled segment. This area is consistent with α-helix composed of 1-4 ¹³C labeled residues (190). The reason for the less-than-expected downshift is i-i+4 H-bonding with unlabeled peptides. In peptides labeled at V³⁶G³⁷G³⁸V³⁹ the dried spectra contains an additional peak at 1596-1602 cm⁻¹. This peak is located at a lower wavenumber and is lower intensity than would be expected from a ¹³C α-helix comprising 4/42 or 4/40 suggesting that the C-terminus of the protein is disordered and the peptides are acting as isolated oscillators (Table 2) (190). This data indicates that in a dry state the peptides adopt a flexible α-helical structure involving K¹⁶L¹⁷V¹⁸ while the V³⁶G³⁷G³⁸V³⁹ sequence close to the C-terminus is unordered. This agrees with previous observations of Aβ containing segments of the APP reconstituted in micelles as well as MD simulations (98, 99, 200). This demonstrates that these dried peptides resemble Aβ prior to membrane release into an aqueous environment, making them a biologically relevant starting material for the study of Aβ structural changes and aggregation.

47
Figure 10. (A) FTIR spectra of dry peptides in the amide I regions. Spectra for unlabeled and isotopically labeled $\text{A} \beta_{1-42}$ and $\text{A} \beta_{\text{pE}3-42}$ peptides and their 1:1 combinations are presented. Gray dotted lines correspond to $\text{A} \beta_{\text{pE}3-42}$, and solid black lines correspond either to $\text{A} \beta_{1-42}$ or to combined samples, as indicated. KLV or VGGV imply the peptides have been labeled at K$^{16}$L$^{17}$V$^{18}$ or V$^{36}$G$^{37}$G$^{38}$V$^{39}$, respectively. In KLV/VGGV or VGGV/KLV samples, the first stretch applies to $\text{A} \beta_{1-42}$ and the second to $\text{A} \beta_{\text{pE}3-42}$. (B) Second derivatives of the corresponding FTIR spectra.

Table 2. Relative amide I content of the $^{13}$C labeled peaks in peptides dried from HFIP. In the columns with two different labels the first one corresponds to $\text{A} \beta_{1-42}$ and the second to $\text{A} \beta_{\text{pE}3-42}$.

<table>
<thead>
<tr>
<th></th>
<th>$\text{A} \beta_{1-42}$</th>
<th>$\text{A} \beta_{\text{pE}3-42}$</th>
<th>1 to 1</th>
<th>KLV/VGGV</th>
<th>VGGV/KLV</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>KLV</td>
<td>12.3%</td>
<td>15.5%</td>
<td>13.3%</td>
<td>13.0%</td>
<td>12.6%</td>
<td>13.3±1.3%</td>
</tr>
<tr>
<td>VGGV</td>
<td>8.2%</td>
<td>12.4%</td>
<td>8.9%</td>
<td>2.2%</td>
<td>7.4%</td>
<td>7.8±3.7%</td>
</tr>
</tbody>
</table>
FTIR of Unlabeled Peptides

After measurement of dried peptides aqueous buffer was added and measurements were taken consecutively (1000 scans takes ~10 minutes). After 10 minutes in 10 mM Phosphate buffer pD 6.8 the peptides and their equimolar combination form type 1 β-turn and intramolecular β-sheet as evidenced by the major peaks at 1673 and 1635-1630 cm$^{-1}$ respectively (Figure 11D) (190). Consistent with previous observations, the peptides retain some α-helical structure evidenced by absorption ~1660 cm$^{-1}$. Peptides in near-physiological buffer conditions have similar absorption peaks and shape indicating formation of type 1 β-turn, α-helix, and intramolecular β-sheet (Figure 11A). After 2 hours the location of the β-sheet was downshifted 2-5 cm$^{-1}$ likely due to H-D exchange. This indicates that the peptides are in a loose conformation allowing solvent access to the majority of peptides residues (Figure 11C). The β-sheet absorbs 1633-1628 cm$^{-1}$ indicating the presence of intramolecular β-sheet as intermolecular β-sheets absorb at a lower wavenumber 1613-1625 cm$^{-1}$. In near physiological conditions Aβ$_{pE3-42}$ contains more α-helix and less β-sheet compared to Aβ$_{1-42}$ indicated by a higher ratio 1660/1630-35 cm$^{-1}$(Figure 11A-C). In low ionic buffer conditions the opposite is true with Aβ$_{1-42}$ containing more α-helix and less β-sheet than Aβ$_{pE3-42}$ (Figure 11D-F). These differences are evident when examining Aβ$_{1-42}$ – Aβ$_{pE3-42}$ difference spectra. In physiological ionic conditions a negative peak at 1660 cm$^{-1}$ and a positive peak at 1620 cm$^{-1}$ indicate more α-helix and less β-sheet in the Aβ$_{pE3-42}$ sample compared to the Aβ$_{1-42}$ (Figure 12A). The opposite is seen in low salt buffer with a large negative peak at 1620 cm$^{-1}$ and a positive peak at 1660 indicating less α-helix and more β-sheet in the Aβ$_{pE3-42}$ (Figure 12C).
Taking the difference spectra of the 1:1 and the weighted sums of the individual peptides show differences caused by peptide interactions. If there were no changes due to peptide interaction this line would be flat. In physiological ionic conditions difference spectra has positive components at 1670 and 1653 cm\(^{-1}\) and a negative component at 1625 cm\(^{-1}\), indicating peptide interaction enhances formation of \(\beta\)-turn and \(\alpha\)-helix and inhibits \(\beta\)-sheet formation (Figure 12B). In low salt a positive component at 1673 cm\(^{-1}\) and a negative one at 1625 cm\(^{-1}\) are present (Figure 12D). This indicates that peptide interaction causes formation of more \(\beta\)-turn and less \(\beta\)-sheet structure. In near-physiological conditions the 1:1 sample more closely resembles the A\(\beta\)\(\text{pE3-42}\) forming more \(\alpha\)-helix and less \(\beta\)-sheet; this agrees with previous data that A\(\beta\)\(\text{pE3-42}\) strongly influences the structure of hybrid samples. In low salt conditions the 1:1 more closely resembles the A\(\beta\)\(\text{1-42}\) forming more \(\beta\)-turn and less \(\beta\)-sheet structure.
Figure 11. FTIR spectra of 50 mM Aβ1-42 (Green) AβpE3-42 (blue) and their equimolar combination (Red) in 50 mM phosphate + 50 mM NaCl pD 7.2 (ABC) and in 10 mM phosphate pD 6.8 (DEF) buffers. Time points shown are 10 minutes (A,D) 60 minutes (B,E) and 120 minutes (C,F). Total peptide concentration is 50 μM.
Figure 12. Difference FTIR spectra of Aβ₁₋₄₂ and Aβᵢ₋₄₂ peptides and their equimolar combinations in 50 mM NaCl + 50 mM phosphate buffer (A, B) and 10 mM phosphate buffer (C, D), pD Spectra in A) and C) show the difference Aβ₁₋₄₂ - Aβᵢ₋₄₂, and those in B) and D) show the difference between 1:1 combination and the normalized sum of the spectra of the two peptides. Blue, green, and red correspond to the peptide samples incubated in a D₂O-based buffer for 10, 60 and 120 min, respectively. Total peptide concentration is 50 μM.

In order to quantitate the relative fractions of secondary structure present peak fitting was performed with peaks being placed based on the second derivative of the spectra (Appendix B). While peak fitting it was noticed that in 50 mM phosphate + 50 mM NaCl pD 6.8 buffer the 1:1 α-helix was downshifted to ~1653 cm⁻¹. This downshift is likely due to helix stabilization. Peaks were assigned to secondary structures based on location of the absorbance peak. Data after 10, 60,
and 120 minutes of hydration was averaged (Table 3). In physiological buffer conditions $\text{A}\beta_{pE3-42}$ contains more $\alpha$-helix and less $\beta$-sheet than $\text{A}\beta_{1-42}$ while the opposite is true in buffer of less ionic content. The 1:1 combination similarly resists $\alpha$-helix-to-$\beta$-sheet conversion.

This is consistent with our previous observations that $\text{A}\beta_{pE3-42}$ is able to retard $\beta$-sheet formation in hybrid samples. The changing $\alpha$-helical propensity based on ionic conditions is evidence that the $\alpha$-helix is located in the N-terminus of the peptides. The $\alpha$-helix of $\text{A}\beta_{1-42}$ can be stabilized by ionic interactions at the N-terminus such as $\text{D}^1\cdot\text{K}^{16}$, $\text{E}^3\cdot\text{K}^{16}$, $\text{D}^1\cdot\text{R}^5$, $\text{R}^5\cdot\text{E}^{11}$. Higher concentrations of ionic charges will weaken this ionic stabilization. The $\text{A}\beta_{pE3-42}$ is missing three N-terminal charges and thus does not form some of these stabilizing ionic interactions.

Table 3. Secondary structures of $\text{A}\beta_{1-42}$, $\text{A}\beta_{pE3-42}$, and their equimolar combination in 50 mM phosphate 50 mM NaCl pD 6.8 (light blue) and 10 mM phosphate pD 6.8 (unshaded) determined by curve fitting of amide 1 spectra. Numbers shown are averages taken after 10, 60, and 120 minutes in buffer. Other refers to all other peaks fit and is primarily composed of unordered structure.

<table>
<thead>
<tr>
<th></th>
<th>$\text{A}\beta_{1-42}$</th>
<th>$\text{A}\beta_{pE3-42}$</th>
<th>1 to 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>$\alpha$-helix</td>
<td>11.0±2.4</td>
<td>18.7±3.2</td>
<td>22.9±3.6</td>
</tr>
<tr>
<td></td>
<td>24.8±5.1</td>
<td>13.6±1.8</td>
<td>16.3±2.1</td>
</tr>
<tr>
<td>$\beta$-sheet</td>
<td>50.4±4.6</td>
<td>43.0±4.4</td>
<td>34.5±3.9</td>
</tr>
<tr>
<td></td>
<td>38.7±4.8</td>
<td>48.9±3.6</td>
<td>34.2±3.2</td>
</tr>
<tr>
<td>$\beta$-turn</td>
<td>18.1±3.3</td>
<td>20.3±1.7</td>
<td>28.4±2.4</td>
</tr>
<tr>
<td></td>
<td>24.0±2.7</td>
<td>19.8±1.3</td>
<td>27.7±3.6</td>
</tr>
<tr>
<td>other</td>
<td>20.5±3.9</td>
<td>18.0±2.2</td>
<td>14.2±1.3</td>
</tr>
<tr>
<td></td>
<td>12.5±3.6</td>
<td>17.7±2.6</td>
<td>21.8±2.7</td>
</tr>
</tbody>
</table>
FTIR of Labeled Peptides

After dry measurement of the labeled peptides buffer was applied and consecutive measurements were taken as with the unlabeled peptides. After ten minutes in both buffers the spectra for the peptide resembles the unlabeled with major peaks $\sim$1673 cm$^{-1}$ and between 1637-1628 cm$^{-1}$ corresponding to type 1 $\beta$-turn and intramolecular $\beta$-sheet respectively (Figure 12). Overlaying the $K^{16}L^{17}V^{18}$ and $V^{36}G^{37}G^{38}V^{39}$ spectra over the unlabeled spectra discussed
previously identifies an additional peak located ~1598-1604 cm$^{-1}$ (Figure 13). This peak can be attributed to the $^{13}$C labeled amino acids in the peptides.

Figure 13. FTIR spectra of A$\beta_{1-42}$ (A,D), A$\beta_{pE3-42}$ (B,E) and, their 1:1 combination (C,F) after 10 minutes in 50 mM phosphate 50 mM NaCl pD 7.2 (A,B,C) and 10 mM phosphate pD 7.2 (D,E,F) buffers. Colors correspond to unlabeled peptide (Red) as well as proteins $^{13}$C- and $^{15}$N-labeled at K$^{16}$L$^{17}$V$^{18}$ (Blue) and V$^{36}$G$^{37}$G$^{38}$V$^{39}$ (green). Total peptide concentration is 50 $\mu$M.

When labeled at K$^{16}$L$^{17}$V$^{18}$ in 50 mM phosphate + 50 mM NaCl pD 6.8 buffer the A$\beta_{pE3-42}$ retains more $\alpha$-helix than A$\beta_{1-42}$ as with the unlabeled peptides (Figure 14 A-C). The A$\beta_{1-42}$ instead forms more type 1 $\beta$-turn structure demonstrated by the larger absorbance at 1673 cm$^{-1}$.  

55
Additionally, the β-sheet absorbance of the Aβ_{1-42} is downshifted 3-5 wavenumbers in comparison to the Aβ_{pE3-42} indicating faster formation of β-sheet compared to the Aβ_{pE3-42}. The 1:1 combination β-sheet peak absorbs ~1633 cm\(^{-1}\) between Aβ_{1-42} and Aβ_{pE3-42}. This agrees with our previous observations that Aβ_{pE3-42} has lower β-sheet propensity than Aβ_{1-42} and could retard β-sheet formation of the Aβ_{1-42} in hybrid samples. When labeled at V\(^{36}\)G\(^{37}\)G\(^{38}\)V\(^{39}\) the Aβ_{pE3-42} contained more β-turn and less β-sheet structure than Aβ_{1-42} indicated by peak heights at 1673 and ~1635 cm\(^{-1}\) respectively (Figure 14 D-F). As with the K\(^{16}\)L\(^{17}\)V\(^{18}\) labeled proteins the β-sheet peak of Aβ_{1-42} is at lower frequencies than Aβ_{pE3-42} indicating faster β-sheet formation.
Figure 14. FTIR spectra of Aβ\textsubscript{1-42} (green), Aβ\textsubscript{pE3-42} (blue) and, their equimolar (red) combinations after 10 (A,D) 60 (B,E) and, 120 (C,F) minutes in 50 mM phosphate 50 mM NaCl pD 7.2 buffer. Peptides are \textsuperscript{13}C- and \textsuperscript{15}N-labeled at K\textsubscript{16}L\textsubscript{17}V\textsubscript{18} (A,B,C) and V\textsubscript{36}G\textsubscript{37}G\textsubscript{38}V\textsubscript{39} (D,E,F). Total peptide concentration is 50 \textmu M.

When 10 mM phosphate pD 6.8 buffer was added to the peptides the Aβ\textsubscript{1-42} formed a higher fraction of β-turn structure indicated by the peak at 1673 cm\textsuperscript{-1} (Figure 15). Additionally, in the K\textsuperscript{16}L\textsuperscript{17}V\textsuperscript{18} labeled peptides the β-sheet peak wavenumber of the Aβ\textsubscript{pE3-42} is shifted several wavenumbers lower than Aβ\textsubscript{1-42} indicating faster β-sheet formation by the Aβ\textsubscript{pE3-42} (Figure 15A-C). The 1:1 β-sheet is again located between the Aβ\textsubscript{1-42} and Aβ\textsubscript{pE3-42} β-sheet wavenumbers indicating that Aβ\textsubscript{1-42} retards β-sheet formation in the hybrid sample. This agrees with our previous data that Aβ\textsubscript{pE3-42} has a lower β-sheet propensity than the Aβ\textsubscript{1-42} and can delay β-sheet formation in hybrid samples in physiological buffer conditions while the opposite is true in buffer of low
Figure 15. FTIR spectra of Aβ1-42 (green), AβpE3-42 (blue) and, their equimolar (red) combinations after 10 (A,D) 60 (B,E) and, 120 (C,F) minutes in 10 mM phosphate pH 7.2 buffer. Peptides are $^{13}$C- and $^{15}$N-labeled at K$^{16}$L$^{17}$V$^{18}$ (A,B,C) and V$^{36}$G$^{37}$G$^{38}$V$^{39}$ (D,E,F). Total peptide concentration is 50 μM.

To facilitate placement of the labeled peak the second derivative was calculated, examination of the second derivative show a peak that can be assigned to the labeled segment ~1603-1598 cm$^{-1}$ (Figure 16). To further quantify this peak as well as to examine secondary structure distribution peak fitting was conducted for spectra taken 10, 60, and 120 minutes after buffer addition (Appendix C). Taking into account our observed intramolecular β-sheet peaks of 1637-1628 cm$^{-1}$ we can predict $^{13}$C-labeled β-sheets to absorb 1601-1592 cm$^{-1}$ therefore we can reliably say that the labeled segment is forming intramolecular β-sheet. As discussed earlier, in
samples containing both $^{13}$C- and $^{12}$C-labeled samples the $^{13}$C-labeled residues can undergo vibrational coupling with either $^{13}$C or $^{12}$C-labeled residues depending on whichever is in close proximity. This coupling changes vibrational frequency with $^{13}$C:$^{13}$C coupling causing a downshift and $^{13}$C:$^{12}$C coupling causing an upshift in absorbance wavenumber. Taken with our previous calculation we can reasonably assign an absorbance 1603-1599 to $^{13}$C-labeled β-sheets undergoing $^{13}$C:$^{12}$C-coupling and the absorbance 1596-1592 to $^{13}$C-labeled β-sheets undergoing $^{13}$C:$^{13}$C-coupling. Therefore, based on the location of the labeled peak in the second derivative we can reasonably conclude that in these samples in any combination neither K$^{16}$L$^{17}$V$^{18}$ nor V$^{36}$G$^{37}$G$^{38}$V$^{39}$ segments are adjacent to themselves or one another.

Figure 16. Second derivative of FTIR spectra taken 10 minutes after the addition of A) 50 mM phosphate + 50 mM NaCl pD 6.8 and B) 10 mM Phosphate buffer pH 6.8. For spectra labeled KLV/VGGV or VGGV/KLV the first corresponds to $\beta_1$-$\beta_{42}$ and the second to $\beta_{pE3}$-$\beta_{42}$. 

59
Aβ Modeling

Although FTIR data generally does not give tertiary or quaternary structural information site-specific $^{13}$C-labeling gave site-specific structural information. This information along with the other data collected here gives structural constraints useful in the modeling of early Aβ oligomers and oligomerization. First, in aqueous buffer both Aβ1-42 and Aβ$_{pE3-42}$ forms a mixture of primarily intramolecular-β-sheet with lesser amounts of, α-helix, β-turn, and unordered structures. This α-helix can be placed at the N-terminus based on data collected in buffers with two different ionic contents indicating that Aβ$_{pE3-42}$ has a higher α-helix propensity than Aβ$_{1-42}$ in physiological conditions while the opposite is true in buffer with low ionic content. Second, the segments K$_{16}$L$_{17}$V$_{18}$ and V$_{36}$G$_{37}$G$_{38}$V$_{39}$ both form intramolecular β-sheet. Third these segments are undergoing $^{13}$C:$^{12}$C coupling meaning they are not adjacent to one another. The final constraint is based on the small size of these peptides as well as the significant fraction of α-helix this makes formation of parallel intramolecular β-sheets impossible. Based on these constraints we propose that the monomeric Aβ is forming a β-hairpin with two β-strands connected by turn structure downstream of K$_{16}$L$_{17}$V$_{18}$ with an N-terminal α-helix (Figure 16). The turn segment is likely stabilized by a salt bridge between D$_{23}$ and K$_{28}$ as predicted in other studies (201). The presence of α-helix with majority β-sheet has been previously observed in Aβ oligomers which display more toxicity to cultured PC12 cells compared to mature fibrils which contain no α-helical component (115).
Figure 17. The amino acid sequence of Aβ_{1-42} arranged in a structure involving a β-hairpin stabilized by D_{23}-K_{28} ionic bridge, and an N-terminal stretch that may assume α-helical conformation. The isotopically labeled amino acids are shaded. Underneath is a ribbon model for Ab monomer, composed of a β-hairpin and an N-terminal α-helix. The segments K_{16}L_{17}V_{18} and V_{36}G_{37}G_{38}V_{39} are both involved in the β-hairpin and are marked by dark blue colors.

These data also give us hints as to how these early monomers aggregate. The lack of $^{13}$C:$^{13}$C coupling exclude the possibility of parallel in-register stacking with the aggregation axis perpendicular to hairpin plane as found in mature fibrils (Figure 17A). Stacking in an anti-parallel arrangement would also cause $^{13}$C:$^{13}$C coupling and can thus be ruled out (Figure 17B). Next we examined oligomerization through interactions between the C-termini or N-termini of neighboring hairpins. The lack of intermolecular β-sheet signal indicates that this interaction is through non-H bonding possibly hydrophobic or ionic. Aggregation in this manner in either a parallel (Figure 17C) or antiparallel (Figure 17D) orientation would again lead to $^{13}$C:$^{13}$C coupling and therefore
can be confidently ruled out. We then examined dimerization through non-H bonding between the C-termini of one hairpin strand with the N-terminus of a neighboring hairpin in either a parallel (Figure 17E) or antiparallel (Figure 17F) manner. In this arrangement there would not be any $^{13}\text{C} : ^{13}\text{C}$ coupling matching our experimental observations and is thus not ruled out. This stacking could take place with the β-strands laterally or in a vertical manner reminiscent of steric zippers. This vertical stacking could take place alternatively between strands (Figure 17E) or alternating between entire hairpins (Figure 17F).
Figure 18. Schematic models for Aβ oligomerization through interactions between the core β-hairpin structures. Two arrows in each molecule represent two β-strands, connected by a loop or turn. The monomers are colored gray and pink, and the isotopically labeled segments are indicated by darker color. In all cases, the structures are stabilized by intramolecular H-bonding and intermolecular non-H-bonding contacts, *i.e.* ionic and/or hydrophobic interactions. The plane of the picture is parallel to the hairpin plane. In A,B the aggregation axis is perpendicular, and in C-F it is coplanar to the picture plane.

Here we conducted FTIR on peptides $^{13}$C-labeled at specific segments in order to obtain site-specific structural information for Aβ$_{1-42}$, Aβ$_{pE3-42}$, and their equimolar combinations. Using this information as well as information obtained in two buffers with distinct ionic content allow us to propose a model for an early monomer composed of a β-hairpin with an N-terminal α-helix.
Additionally, we propose that these monomers aggregate through non-H-bonding interactions between the N-terminus of one hairpin and the C-terminus of another. These oligomers are structurally distinct from mature fibrils and are formed via a different mechanism of aggregation. The consistency of this data throughout repeated experiments, in spite of the polymorphic nature of these proteins, lends credibility to these results.
Mutual inhibition of fibrillogenesis by Aβ peptides

Next, we sought to characterize the transitions and intermediate structures during oligomer formation. The toxic Aβ species is thought to be created sometime during the transition from the α-helical monomer to the mature cross β-fibrils. However, it is unknown whether these oligomers are formed as intermediates during fibrillogenesis or are formed via alternative pathways. We sought to answer this question by examining the α-to-β transition of the peptides. To accomplish this we used a novel approach, hydration from gas phase, (see methods) based on our previous use of atmospheric humidity to induce structural changes in Aβ (Figure 6).

Individual Peptides

Prior to examining hybrid samples we first characterized the behavior of individual peptides. After desiccating the proteins onto the windows as described earlier, spectra of the dried peptide was collected. These spectra indicate that both $^{13}$CAβ$_{1-42}$ and Aβ$_{pE3-42}$ are forming primarily α-helical structure shown by peaks at 1616 and 1657 cm$^{-1}$ respectively (Figure 18). In the $^{13}$CAβ$_{1-42}$ spectra a shelf present ~1590 indicates presence of a small amount of β-sheet and the peak ~1673 cm$^{-1}$ likely corresponds to residual TFA from peptide synthesis.
Figure 19. FTIR spectra of 50 μM AβpE3-42 (red) and 13CAβ1-42 (blue) in HFIP added to FTIR windows followed by HFIP removal by vacuum desiccation.

Following measurement of dried peptides structural transitions were initiated by beginning the flow of D₂O laden N₂ gas into the sample chamber. The buildup of D₂O within the chamber is indicated by increasing intensity of spectral features generated by D₂O stretching ~2500 (Figure 20). This data indicated that D₂O saturation level reached one third of maximum after 5 minutes and then slowly rose until maximum saturation is reached approximately 3 hours later. After the onset of D₂O hydration the peak associated with the 13CAβ1-42 α-helix rapidly diminished while a peak corresponding to β-sheet ~1590 cm⁻¹ quickly grew indicating a rapid initial rate of α-helix-to-β-sheet transition (Figure 21A). The peak ~1673 cm⁻¹ is unchanged throughout hydration and can be attributed to TFA. Hydration of the AβpE3-42 caused a decrease in α-helix and a corresponding increase in β-sheet content indicated by growth of a peak at 1633 cm⁻¹ (Figure 21B).
Over time, the reduction in α-helical intensity revealed an additional peak at 1673 cm\(^{-1}\) which we have previously attributed to type 1 β-turns. Additionally, the Aβ\(_{1-42}\) retained an amide II absorbance while the Aβ\(_{pE3-42}\) amide II was fully deuterated, as previously observed. This α-to-β transition is easily observed by looking at the second derivative of the initial spectra and one after five hours of gas phase hydration (Figure 21C,D). Examination of second derivatives reveal a component at 1613 cm\(^{-1}\) in \(^{13}\)CAβ\(_{1-42}\), this peak indicates retention of α-helical structure (Figure 21C). The downshift in wavenumber is likely due to amide dueteration throughout hydration. A small component ~1660 cm\(^{-1}\) in the AβpE likely corresponds to some residual α-helix as well (Figure 21D).
Figure 20. FTIR Spectra of Aβ₃₉₋₄₂ sample in D₂O absorbance region at various times of continuous injection of D₂O-saturated nitrogen. The intensity of D₂O asymmetric stretching vibrational-rotational mode increases as D₂O vapor is being pumped into the sample compartment of the FTIR instrument. The spectra have been stacked for clarity.
Figure 21. FTIR spectra of $^{13}$C-Aβ1-42 (A) and AβpE3-42 (B) dried on a CaF$_2$ window (black lines) and upon injection of D$_2$O-saturated nitrogen for ~5 hours (blue to red). Amide I areas have been normalized. Time points of consecutive spectra can be determined from data of Fig. 21. The second derivatives of spectra corresponding to the dry and after five hours of vapor hydration for the Aβ1-42 (C) and AβpE3-42 (D).

Although both peptides transitioned from α-helix to β-sheet the kinetics of this transition were quite different. The AβpE3-42 transition occurs much slower at first and then more rapidly later on. To examine the kinetics of this transition we plotted $A_\alpha/A_\beta$ as well as the height of the amide II peak versus time (Figure 22). In the Aβ1-42 for the first hour, the $A_{1590}/A_{1616}$ rapidly increased.
while the amide II height rapidly diminished (Figure 22A). After an hour this trend continued but at a reduced rate. Conversely, the AβpE3-42 transitions were sigmoidal in behavior. Little change occurred in the first hour, followed by rapid change in both amide II height and A_{1633}/A_{1658} (Figure 22B). The delayed β-sheet formation of the AβpE compared to the unmodified peptide agrees with our previous observations.

![Figure 22. Dependence of β-structure formation (red) in 13C-Aβ1-42 (A) and AβpE3-42 (B) and amide II intensities (blue) on time of pumping D2O-saturated nitrogen into the sample compartment.](image)

**Combined Sample α-to-β Transition**

Following measurement of the individual peptides we examined the structural effects of combination of the peptides. Two peptide ratios were used a 9:1 (Aβ1-42:AβpE3-42) ratio and an equimolar ratio, as we used in previous experiments. Two samples were prepared and examined sequentially while exposed to the same vapor environment, the first has both peptides dried together on one side of the CaF2 FTIR window, in the other sample the two peptides are dried on opposite sides of the CaF2 window so the signal from both peptides is present in the spectra but
peptide interaction is not occurring (See Methods). When dried at either ratio, both Aβ1-42 and AβpE3-42 form α-helix indicated by absorbance peaks at 1617-1619 and ~1658 cm⁻¹ respectively (Figure 23 A,B). The α-helix location is unchanged between separated and combined samples implying a lack of ¹³C:¹²C coupling. Therefore, we can conclude that in the α-helical state the peptides are not interacting. Curiously in all samples the ¹³CAβ1-42 α-helix absorbs at a lower intensity than would be expected from peptide ratios.

Both peptides when either separated or combined at a 9:1 ratio underwent α-to-β transition in response to D₂O vapor. After 5 hours of vapor hydration, the α-helical peaks have diminished and in their place β-sheet peaks corresponding to both peptides have formed, as well as a peak at 1673 cm⁻¹ corresponding to TFA with some likely contribution from AβpE3-42 β-turn (Figure 24A,B). In the separated sample the AβpE3-42 β-sheet was located at 1625 cm⁻¹ while in
combination it absorbed weaker and higher at 1639 cm\(^{-1}\). These peaks could normally be assigned to inter- and intramolecular \(\beta\)-sheet respectively. However, the high molar ratio of \(^{13}\text{CA}\beta_{1-42}\) means that this upshift could also be caused by transition dipole coupling, thus further investigation is required. Examination of the second derivative of spectra taken after 5 hours of vapor hydration (Figure 24C,D), shows absorbance peaks at 1625 and 1639 cm\(^{-1}\) in both separate and combined samples. The presence of these peaks in both samples implies that both intra- and intermolecular \(\beta\)-sheets are formed in both samples but co-incubation with unmodified \(\text{A}\beta\) shifts structural propensity of \(\text{A}\beta\text{pE}\) from inter- to intramolecular \(\beta\)-sheet. In \(^{13}\text{CA}\beta_{1-42}\) the \(\beta\)-sheet is located at 1585 and 1587 cm\(^{-1}\) in separate and combined samples respectively. These peaks indicate presence of intermolecular or cross \(\beta\)-sheet, the small upshift in the combined sample is likely due to \(^{13}\text{C}:^{12}\text{C}\) coupling with unlabeled \(\text{A}\beta\text{pE3-42}\). The lack of a structural shift in the \(^{13}\text{CA}\beta_{1-42}\) is expected, due to the high molar excess of \(\text{A}\beta_{1-42}\) and the solid nature of the sample there is likely little interaction between most \(\text{A}\beta_{1-42}\) peptides and \(\text{A}\beta\text{pE3-42}\).
Figure 24. FTIR spectra of \( \text{A}\beta_{pE3-42} \) and \( ^{13}\text{C}-\text{A}\beta_{1-42} \) peptides at opposite sides of a CaF\(_2\) window (A) or combined on the same side of a window (B) at a 9:1 mole ratio. Black lines are spectra of dry samples. Change in color from blue to red corresponds to injection of D\(_2\)O-saturated nitrogen for \(~5\) hours. Amide I areas have been normalized. Time intervals between consecutive spectra can be determined from data of Fig. 26. C,D) Second Derivative of FTIR spectra after 5 minutes (blue) and 5 hours (red) of hydration for both separate (C) and combined (D) peptides.

The equimolar samples also undergo \( \alpha\)-to-\( \beta\) transition. Diminishing of the \( \text{A}\beta_{pE3-42} \) \( \alpha\)-helical peak throughout hydration again uncovers the peak located at 1673 cm\(^{-1}\) likely composed of both TFA from the \( ^{13}\text{C}\alpha_{1-42} \) and \( \beta\)-turn of the \( \text{A}\beta_{pE3-42} \) (Figure 25A,B). Along with this peak are peaks corresponding to \( \beta\)-sheet of both peptides. After five hours of hydration from gas phase the \( \beta\)-sheet peak of \( \text{A}\beta_{pE3-42} \) the major peak is located at 1628 when separate and 1638 cm\(^{-1}\) when combined.
When separate the Aβ1-42 β-sheet peak is located at 1586 cm\(^{-1}\) while in combination it shifts to 1597 cm\(^{-1}\). For both peptides the former can be attributed to intermolecular β-sheet while the latter can be attributed to intramolecular β-sheet. Examination of the second derivative of 5 hour spectra show peaks corresponding to intra- and inter β-sheets for both peptides (i.e. peaks at 1637, 1628, 1597, and 1586 cm\(^{-1}\)) indicating that the shifted peak comes from structural shifts and not simply \(^{13}\)C:\(^{12}\)C coupling (Figure 25C,D). Additionally, these spectra contain peaks at 1656-1654 and 1617-1616 cm\(^{-1}\) these peaks likely represent residual α-helix of Aβ\(_{pE3-42}\) and Aβ1-42 respectively, indicating incomplete α-to-β transition. This data along with the data from the 9:1 ratio indicate that Aβ\(_{pE3-42}\) forms more intra- than inter-molecular β-sheet in the presence of Aβ1-42, while Aβ1-42 similarly forms more intra- than inter-molecular β-sheet in the presence of Aβ\(_{pE3-42}\). This relationship is demonstrated by overlaying the separated and combined samples spectra after 5 hours of D\(_2\)O hydration (Figure 26).

To quantify this shift we examined the ratio \(A_{\text{intra}}/A_{\text{inter}}\) after five hours which gives the ratio of intra to inter-β-sheet present in the sample, which will henceforth refer to as \(R_\beta\). Taking \(R_{\beta\text{comb}}/R_{\beta\text{sep}}\) allows quantification of the change in this ratio caused by peptide interaction (Table 5). The values for the 9:1 \(^{13}\)CAβ1-42 are not calculated as it did not form any significant fraction of intramolecular β-sheet. For both Aβ1-42 and Aβ\(_{pE3-42}\) \(R_{\beta\text{comb}}/R_{\beta\text{sep}}\) is above 1 at both 9:1 and 1:1 ratios indicating shifts in β-sheet formation caused by peptide interaction. This is compelling evidence that the peptides act upon one another to mutually inhibit cross β-sheet formation. Curiously, the structural components are consistent with their molar ratios after hydration in both.
9:1 and 1:1 samples. This means that the altered ratios observed in dry samples is caused by a lowered extinction coefficient for $^{13}\text{CA}\beta_{1-42} \alpha$-helical structure and not improper peptide ratios.
Figure 25. FTIR spectra of Aβ_{PE3-42} and ^13C-Aβ_{1-42} peptides at opposite sides of a CaF₂ window (A) or combined on the same side of a window (B) at a 1:1 mole ratio. Black lines are spectra of dry samples. Change in color from blue to red corresponds to injection of D₂O-saturated nitrogen for ~5 hours. Amide I areas have been normalized. Time intervals between consecutive spectra can be determined from data of Fig. 26. C,D) Second Derivative of FTIR spectra after 5 minutes (blue) and 5 hours (red) of hydration for both separate (C) and combined (D) peptides.
Figure 26. FTIR spectra for 9:1 (A) and 1:1 (B) molar ratios taken after 5 hours of continuous vapor hydration. The teal spectra corresponds to separated peptides while the green is the peptides in combination.
Table 4. Quantitative data describing α-helix to β-sheet transitions in Aβ₃-₄₂ and ¹³C-Aβ₃-₄₂ peptides at opposite sides of a CaF₂ window or combined together at one side of a window at 1:9 or 1:1 molar ratios. Δν is the shift in wavenumbers from α-helix to β-sheet and ΔΔν is the difference between combined and separated samples. Aₜₐₙₜra and Aₐₛₜₜₙ correspond to the major b-sheet peaks as found experimentally and shown in the table.

<table>
<thead>
<tr>
<th></th>
<th>9:1 (¹³Cβ₁-₄₂:Aβ₃-₄₂)</th>
<th>1:1 (¹³Cβ₁-₄₂:Aβ₃-₄₂)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Aβ₃-₄₂</td>
<td>¹³Cβ₁-₄₂</td>
</tr>
<tr>
<td>α→β Transition</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Separate</td>
<td>1659→1625</td>
<td>1617→1585</td>
</tr>
<tr>
<td>Peak Shift Δν</td>
<td>34</td>
<td>32</td>
</tr>
<tr>
<td>(cm⁻¹)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rₜₐₙₜra (Aₜₐₙₜra/Aₐₛₜₜₙ)</td>
<td>0.97</td>
<td>-</td>
</tr>
<tr>
<td>Combined</td>
<td>1659→1639</td>
<td>1617→1587</td>
</tr>
<tr>
<td>Peak Shift Δν</td>
<td>20</td>
<td>30</td>
</tr>
<tr>
<td>Rₜₐₙₜra (Aₜₐₙₜra/Aₐₛₜₜₙ)</td>
<td>1.08</td>
<td>-</td>
</tr>
<tr>
<td>ΔΔν</td>
<td>14</td>
<td>2</td>
</tr>
<tr>
<td>Rβₜₐₙₜra/Rβₜₐₙₜra (Aₜₐₙₜra/Aₐₛₜₜₙ)</td>
<td>1.11</td>
<td>-</td>
</tr>
</tbody>
</table>

The kinetics of α→β transition was examined by taking the ratio of the absorbance intensity at the peaks associated with β-sheet in both separated and combined samples over the intensity of the α-helical peak, and tracking it against time of hydration (Figure 27). At a 9:1 ratio
there is very little shift in the β-sheet peak of the $^{13}$CAβ₁₋₄₂ between the separated and combined samples as expected due to the low ratio of Aβ/pE and solid nature of the samples. When the kinetics of β-sheet formation in both separated and combined samples is examined they closely resemble one another as well as the Aβ₁₋₄₂ individually, in that they undergo transition rapidly initially before then slowing but continuing to transition with time. The Aβₚₑ₃₋₄₂ initially underwent transition more slowly than the unmodified peptide, in agreement with previous observations. In both separate and combined samples the Aβₚₑ₃₋₄₂ forms more inter- than intramolecular β-sheet. However, the difference between the two narrows in combined samples indicating a shift from inter- to intra-β-sheet formation (Black and white circles Figure 27 A,B).

In the 1:1 samples the kinetics are similar with Aβ₁₋₄₂ transitioning rapidly at first and then slowing while Aβₚₑ₃₋₄₂ transition appeared to speed up with time (Figure 27 C,D). Examination of β-sheet formation in combination yields strong evidence that the peptides mutually inhibit intermolecular β-sheet formation in favor of intramolecular β-sheet formation. For both peptides, when separated intermolecular β-sheet formation is favored while the opposite is true in combined samples (White circles and squares are increased compared to colored in separate samples while the opposite is true in combination). Interestingly the effect of Aβₚₑ₃₋₄₂ on Aβ₁₋₄₂ appeared to be most pronounced after 3 hours, with the rate of intramolecular β-sheet formation increasing greatly compared to the formation of intermolecular β-sheet.
Figure 27. Changes in β-sheet/α-helix amide I intensity ratios with time of pumping D$_2$O-saturated nitrogen. A, B: Aβ$_{pE3-42}$/^{13}C-Aβ$_{1-42}$ = 1:9; C, D: Aβ$_{pE3-42}$/^{13}C-Aβ$_{1-42}$ = 1:1. A, C: peptides are physically separated, i.e. are at opposite sides of a CaF$_2$ window, B, D: peptides are combined at one side of a CaF$_2$ window. Symbols in A are identical to B, and symbols in C is identical to D. Black graphs describe transitions in Aβ$_{pE3-42}$, red graphs describe transitions in ^{13}C-Aβ$_{1-42}$. Aβ$_{pE3-42}$ and ^{13}C-Aβ$_{1-42}$

This data indicates that Aβ$_{pE3-42}$ and Aβ$_{1-42}$ mutually inhibit intermolecular β-sheet formation of one another, instead promoting formation of intramolecular β-sheet. This data agrees with previous observations of the Aβ$_{pE3-42}$ ability to inhibit cross β-sheet formation of the Aβ$_{1-42}$
(Figures 7,9). Kinetic data shows a decelerated rate of intermolecular β-sheet formation in mixed samples supporting this conjecture (Figure 27). Conceivably, this could be caused by intervention of non-identical peptide molecules into structures formed by the other peptide shifting the H-bonding from intermolecular to intramolecular. Peptides forming intermolecular β-sheets eventually go on to form mature fibrils while these intramolecular β-sheets likely resemble the β-hairpins we described earlier (Figure 16). The presence of residual α-helix agrees with earlier findings and supports this conclusion. It can therefore be concluded that Aβ1-42 and AβpE3-42 mutually inhibit formation of intermolecular β-sheet, instead promoting off-pathway formation of mixed α/β hairpins (Figure 28). This conclusion agrees with previous observations of delayed fibrillogenesis of mixed samples (Figure 5).
Figure 28. Scheme for aggregation of Aβ<sub>pE3-42</sub> (gray), Aβ<sub>1-42</sub> (red), and their combination, accompanied with an α-helix to β-sheet transition. At the N-terminus of Aβ<sub>1-42</sub> there are 3 additional charges, a positive charge of the N-terminal α-amino group and 2 negative charges of the side chains of Asp1 and Glu3. Helices are shown as spirals, β-strands as arrows, and H-bonds as black bars.

**MTS Viability Assay**

We next wished to examine the effect of these Aβ hetero-oligomers on Aβ aggregates through collaboration with Dr. Kenneth Teter and Dr. Lucia Cilenti. In this data the most toxic species is the equimolar combination of Aβ<sub>pE3-42</sub> and Aβ<sub>1-42</sub> at two hours of aggregation (Figure 29). This is the time period where the greatest population of hetero-oligomer is thought to exist. This data demonstrates the enhanced cytotoxic properties of these hetero-oligomers.
Aβ Mediated Membrane Calcium Leakage

The formation by Aβ of calcium permeable membrane pores is a hypothesized mechanism of Aβ mediated cytotoxicity in AD. To examine the effect of these oligomers, Aβ aggregates were added to a solution containing calcium bound in unilamellar lipid vesicles composed of 60% POPC 30% POPG and 10% cholesterol after 2 and 24 hours of aggregation. The release of calcium from vesicles was demonstrated via increase in fluorescence of Quin-2. Maximum fluorescence is demonstrated by popping all of the vesicles with triton-X. The results of this are striking, at two hours of aggregation Aβ₁-₄₂ does not induce any greater calcium release than buffer control.
However, Aβ<sub>pE3-42</sub> as well as 9:1 and 1:1 combinations induce significant release of calcium (Figure 30A). At 24 hours of aggregation the combinations had a lesser effect than at two hours, consistent with pore formation by oligomers but not mature fibrils (Figure 30B). Curiously, the Aβ<sub>pE3-42</sub> actually had a greater effect on calcium release at 24 hours than 2 hours. Additionally, at 24 hours the 9:1 had a greater effect than the 1:1.

![Figure 30](image)

Figure 30. Vesicular calcium release as assayed by Quin-2. Aβ peptides were added to vesicles after 2 hours (A) and 24 hours (B) of aggregation via stirring at 37 °C. Data for release via Aβ<sub>1-42</sub> (blue), Aβ<sub>pE3-42</sub> (red), 9:1 (green) 1:1 (teal) and buffer control (black) are shown. Peptides were added following two measurements to establish a baseline, 0.5% Triton X-100 was added to the control after 6 measurements to disrupt vesicles and measure maximum fluorescence.

This data demonstrates that these hetero-oligomers do in-fact induce a significant drop in cellular viability compared to individual peptides. These hetero-oligomers also induced greater release of intra-vesicular calcium. The far greater effect of Aβ<sub>pE3-42</sub> at 24 hours as well as the greater effect of 9:1 than 1:1 at 24 hours, is not consistent with toxicity data. To confirm these results follow up studies are being conducted. If confirmed, this data implies that formation of
calcium pores in lipid membranes may not be the primary Aβ-mediated pathway of cellular dysfunction in AD.
CHAPTER FIVE: CONCLUSIONS

Recent evidence has shifted focus from fibrillar to soluble oligomeric species of Aβ as the primary cytotoxic species in AD. Due to the difficulty of their study, namely their structural heterogeneity, dynamics, and polymorphic nature, little is known about the structure and formation of Aβ oligomers. Pyroglutamylated Aβ are major species of Aβ in the AD brain displaying increased toxicity. Studies have demonstrated the ability of AβpE3-42 to increase the toxicity of unmodified Aβ in low molar ratio through structural changes however, little is known about the mechanism.

This project sought to investigate Aβ oligomer structure. In particular we aimed to examine the structural effect of AβpE on unmodified Aβ. Current evidence implicates these oligomers as the cytotoxic Aβ agent in AD (38, 46). Pyroglutamylated Aβ species make up a significant fraction of the soluble Aβ in AD brains. AβpE3-42 has been demonstrated to cause significant changes to oligomers of Aβ1-42 and AβpE3-42, altering both their structure and toxicity, even when it is present in low molar ratio (44). We first sought to examine the effects of AβpE3-42 on the structure and fibrillization kinetics of Aβ1-42. Data collected via CD indicate that AβpE3-42 delays β-sheet formation of the unmodified peptide in mixed samples. TEM images of the unmodified Aβ collected after two hours of aggregation contain mature fibrils while samples of AβpE and mixed samples contained greater numbers of globular aggregates. FTIR data indicates that AβpE inhibits cross β-sheet formation of the unmodified peptide, thus retarding fibrillogenesis. Inhibiting fibril
formation may increase the population of Aβ oligomers or promote formation of off-pathway aggregates of enhanced toxicity.

We next sought to characterize the early oligomers of AβpE and unmodified Aβ as well as the structural changes upon co-incubation. To further investigate the structure of Aβ oligomers we utilized peptides selectively $^{13}$C-labeled at two specific segments $K^{16}L^{17}V^{18}$ and $V^{36}G^{37}G^{38}V^{39}$. These allow site specific determination of protein secondary structure. Data was collected of Aβ$_{1-42}$, Aβ$_{pE3-42}$, and, their equimolar combination labeled at two locations and in two buffers of different ionic content. This data indicates that early oligomers are composed of α-helix, intramolecular β-sheet, and β-turn structure, and that the labeled segments were forming β–sheets. Changes in α-helical content in different buffer conditions indicate that the a-helix is located at the N-terminus. Additionally, the carbon coupling of labeled residues indicates a lack of $^{13}$C:$^{13}$C coupling giving both tertiary and quaternary structural insight. These data allow us to propose a possible structure for the monomeric Aβ namely a β-hairpin with an N-terminal α-helix and a β-turn occurring downstream of $K^{16}L^{17}V^{18}$. Data indicates that oligomerization likely occurs through non H-bonding interactions between neighboring β-hairpin strands.

After structural characterization of early peptides we sought greater detail on the early dynamics of oligomerization. In the plasma membrane as well as HFIP Aβ peptides are α-helical. In buffer they quickly form β-sheets and begin to aggregate. We have already observed that Aβ$_{pE3-42}$ inhibits this β-sheet formation of the Aβ$_{1-42}$ in aqueous buffer. To observe these changes we gradually hydrated the peptides using D$_2$O vapor. Upon exposure to vapor both peptides undergo
α-to-β transition but with different kinetics. Aβ1-42 transitions rapidly in the first hour and continued to transition slowly afterwards, while AβpE3-42 transitioned in a sigmoidal manner. When combined the peptides exerted a mutual effect upon one another to intermolecular β-sheet formation instead forming intramolecular β-sheets. Data from vesicle calcium release studies and MTS assays indicate that in combination the peptides have a more pronounced effect on cellular viability than the peptides individually and induce greater release of calcium than the unmodified peptide alone. Thus hybrid AβpE and unmodified samples exhibit enhanced cytotoxicity possibly due to increased formation of off pathway mixed α/β oligomers instead of the intermolecular β-sheet structures that make up mature fibrils. These hetero-oligomers induce greater calcium release from lipid membranes and exert a greater effect on cellular viability than the unmodified Aβ.

Previous studies on Aβ oligomers have found an antiparallel orientation while studies on mature fibrils show a parallel in-register orientation. In FTIR spectra antiparallel β-sheet is indicated by a major peak 1636-1630 cm\(^{-1}\) and a minor peak 1680-1670 cm\(^{-1}\). Although several spectra appear to contain a peak corresponding to antiparallel β-sheet (Figures 6, 16A,B), the low intensity of this peak makes it impossible to differentiate from other structural components. In AβpE3-42 this peak is located in a similar location to β-turn and TFA while in \(^{13}\)CAβ1-42 this peak (~1643-1633 cm\(^{-1}\)) corresponds with AβpE3-42 β-sheet absorbance. Therefore, it is not possible to determine whether these oligomers are in a parallel or antiparallel orientation. Curve fitting of spectra indicate that α-helical and β-sheet fractions of peptides vary to a degree (Tables 3,4). This
indicates low barrier energy between these structures; and represents a possible source of Aβ polymorphism.

**Significance**

It is believed that the toxic Aβ species in AD is formed during the transition from the α-helical structure formed prior to lipid membrane exit to the intermolecular β-sheet structure found in mature fibrils. Here we characterized this transition as well as proposing a data-based model of early Aβ monomers as well as aggregation. Data indicate that Aβ₁₋₄₂ and AβₚE₃₋₄₂ mutually inhibit cross-β-sheet formation of one another instead forming mixed α/β hairpins. Inhibition of cross β-sheet formation delayed fibrillogenesis and lead to an increase in the population of globular aggregates. Studies have found oligomers of mixed α/β content to display enhanced cytotoxicity (114-116). These hetero-oligomers had a greater effect on the viability of PC12 cells than either peptide alone indicating their potent effect. Additionally, vesicle calcium release assays demonstrate that this effect may in part be due to enhanced formation of calcium permeable pores in lipid membranes. This work highlights the importance of hetero-oligomers in the pathogenesis of AD. This data gives insight into oligomer structure and formation as discussed in figure 1 (Figure 31).
Figure 31. Update of Figure 1 using data collected during this work. Mixed populations of Ab1-42 and AbpE3-42 promote formation of hetero-oligomers via a non-fibrillogenic pathway. These oligomers display increased cytotoxicity to PC12 cells possibly through the formation of calcium permeable membrane pores leading to loss of Ca\(^{2+}\) homeostasis.

**Future Studies**

Targets for future study include Aβ1-40 and its pyroglutamylated counterpart the AβpE3-40. In vivo Aβ populations are heterogeneous but little is known about the behavior of mixed peptide populations. These species are prevalent in the AD brain and examination should be conducted on whether they have similar structural effects upon one another. If they possess the same mutual inhibitory relationship, it is strong evidence that this effect may occur with other pyroglutamylated
Aβ species. We also seek a method to stabilize oligomers for the time scales necessary for ssNMR analysis. Of particular interest is stabilization of oligomers formed in physiologically relevant conditions without using methods that may induce structural changes. High resolution structural data from ssNMR would represent strong supporting evidence for the β-hairpin model proposed here. Follow-up studies should also be conducted to investigate inconsistencies between vesicular calcium release and cellular viability studies.
APPENDIX A: PEAK FITTING OF DRY SPECTRA
Peak fitting of Dry FTIR spectra. The original spectra (blue), peak fit (dotted red), and baseline (black) are shown. Fit peaks corresponding to alpha helix (orange) and the labeled segment (pink) are also shown. Peaks shown in grey are considered other in area concentration and correspond primarily to unordered structure. Peaks corresponding to side chain interactions are dotted grey and are not included in area calculations.
APPENDIX B: PEAK FITTING UNLABELED PEPTIDES
Peak Fit Spectra of Aβ_{1-42} Aβ_{4E3-42} and their equimolar combination in 10 mM phosphate pD 6.8 buffer labeled here as low salt as well as 50 mM phosphate 50 mM NaCl pD 6.8 labeled here as high salt for 10, 60, and 120 minutes. The experimental measurement is shown in Blue while the Red dotted line is the sum of all components, fit peaks correspond to turn (green), α-helix (orange), and β-sheet (purple) unattributed peaks are shown in grey and are primarily composed of unordered structure. Peaks corresponding to side chain interactions are shown in dotted grey and are not included in area calculations. The second derivative of the experimental spectra is shown in black underneath. Total peptide concentration is 50 μM.
Ab42 60 Minutes High Salt

Absorbance

2nd Deriv.

Wavenumber (cm\(^{-1}\))

1700 1680 1660 1640 1620 1600
AbpE 10 Minutes High Salt

Absorbance

2nd Deriv.

Wavenumber (cm⁻¹)

1700 1680 1660 1640 1620 1600
1:1 60 Minutes High Salt

Absorbance

2nd Deriv.

Wavenumber (cm⁻¹)
AbpE 120 Minutes Low Salt

Absorbance

2nd Deriv.

Wavenumber (cm⁻¹)
APPENDIX C: PEAK FITTING OF LABELED PEPTIDES
Curve fit spectra of $^{13}$C-labeled $\text{A\beta}_{1-42}$, $\text{A\beta}_{\text{PE3-42}}$ and their equimolar combination in 10 mM phosphate pD 6.8 buffer (low salt conditions) as well as 50 mM phosphate 50 mM NaCl pD 6.8 (physiological buffer) for 10, 60, and 120 minutes. Peptides were $^{13}$C- and $^{15}$N-labeled at either K$^{16}$L$^{17}$V$^{18}$ or V$^{36}$G$^{37}$G$^{38}$V$^{39}$. The experimental measurement is shown in Blue while the Red dotted line is the sum of all components, fit peaks correspond to turn (green), $\alpha$-helix (orange), and $\beta$-sheet (purple) unattributed peaks are shown in grey and are primarily composed of unordered structure. Peaks corresponding to side chain interactions are shown in dotted grey and are not included in area calculations. The second derivative of the experimental spectra is shown in black underneath. Total peptide concentration is 50 $\mu$M.
Table 5. Distribution of secondary structures in 50 mM phosphate 50 mM NaCl pH 6.8 as calculated by curve fitting. Numbers are the averages at 10, 60, and 120 minutes in buffer, label combination refers to the fraction of the peak corresponding to the $^{13}$C-label in KLV/VGG and VGGV/KLV spectra. Components counted as other, primarily unordered structure, are not included in the table.

<table>
<thead>
<tr>
<th>High Salt</th>
<th>$\beta$-turn</th>
<th>$\alpha$-helix</th>
<th>$\beta$-sheet</th>
<th>$^{13}$C-Label KLV</th>
<th>$^{13}$C-Label VGGV</th>
<th>$^{13}$C-Label Combination</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$\beta_{1-42}$</td>
<td>$\beta_{\text{pE3-42}}$</td>
<td>$1:1$</td>
<td>$\alpha$-helix</td>
<td>$\beta$-sheet</td>
<td>$^{13}$C-Label Combination</td>
</tr>
<tr>
<td></td>
<td>19.5 ± 8.3</td>
<td>27.7±5.0</td>
<td>22.1±3.5</td>
<td>24.4±10.7</td>
<td>41.1±5.0</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>27.7±5.0</td>
<td>18.1±10.6</td>
<td>22.1±3.5</td>
<td>45.4±5.6</td>
<td>36.2±10.8</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>22.1±3.5</td>
<td>26.9±7.2</td>
<td>26.9±7.2</td>
<td>36.2±10.8</td>
<td>36.2±10.8</td>
<td>6.1±2.8</td>
</tr>
<tr>
<td></td>
<td>7.4±1.0</td>
<td>8.0±1.5</td>
<td>5.8±0.7</td>
<td>10.3±0.8</td>
<td>9.9±0.4</td>
<td>10.4±0.5</td>
</tr>
<tr>
<td></td>
<td>10.3±0.8</td>
<td>10.4±0.5</td>
<td>10.4±0.5</td>
<td>10.4±0.5</td>
<td>10.4±0.5</td>
<td>6.1±2.8</td>
</tr>
<tr>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>6.1±2.8</td>
</tr>
</tbody>
</table>
Ab42 KLV 60 Minutes

Absorbance

2nd Deriv.

Wavenumber (cm⁻¹)
Absorbance

2\textsuperscript{nd} Deriv

Wavenumber (cm\textsuperscript{-1})
Ab4VGGV 10 Minutes

Absorbance

2nd Deriv.

Wavenumber (cm\(^{-1}\))
Ab42 VGGV 120 Minutes

Absorbance

2nd Deriv.

Wavenumber (cm$^{-1}$)
Low Salt Conditions

Table 6. Distribution of secondary structures in 10 mM phosphate pD 6.8 as calculated by curve fitting. Numbers are the averages at 10, 60, and 120 minutes in buffer, label combination refers to the fraction of the peak corresponding to the $^{13}$C-label in KLV/VGG and VGGV/KLV spectra. Components counted as other, primarily unordered structure, are not included in the table.

<table>
<thead>
<tr>
<th>Low Salt</th>
<th>$A\beta_{1-42}$</th>
<th>$A\beta^{\beta E3-42}$</th>
<th>1:1</th>
</tr>
</thead>
<tbody>
<tr>
<td>$\beta$-turn</td>
<td>26.2±5.2</td>
<td>21.3±3.6</td>
<td>25.0±5.5</td>
</tr>
<tr>
<td>$\alpha$-helix</td>
<td>21.8±7.9</td>
<td>21.5±8.1</td>
<td>15.3±6.0</td>
</tr>
<tr>
<td>$\beta$-sheet</td>
<td>34.2±9.5</td>
<td>35.2±10.2</td>
<td>36.5±8.5</td>
</tr>
<tr>
<td>$^{13}$C-Label KLV</td>
<td>4.9±0.6</td>
<td>6.7±0.5</td>
<td>6.3±0.6</td>
</tr>
<tr>
<td>$^{13}$C-Label VGGV</td>
<td>7.4±0.4</td>
<td>12.9±0.4</td>
<td>14.2±0.2</td>
</tr>
<tr>
<td>$^{13}$C-Label Combination</td>
<td>-</td>
<td>-</td>
<td>8.2±1.3</td>
</tr>
</tbody>
</table>
Absorbance

AbpE VGGV 120 Minutes

2\textsuperscript{nd} Deriv.

Wavenumber (cm\textsuperscript{-1})

1700 1680 1660 1640 1620 1600
1:1 VGGV 10 Minutes

Absorbance

$2^{nd}$ Deriv.

Wavenumber (cm$^{-1}$)


alters APP processing and Tau expression in iPSC-derived neurons. Human Molecular Genetics 23:3523-3536.


familial Alzheimer’s disease and increases amyloid-beta 42 to amyloid-beta 40 ratio.
Neurobiology of Aging 35:6.
71. Hashimoto, Y., and M. Matsuoka. 2014. A mutation protective against Alzheimer’s disease
renders amyloid beta precursor protein incapable of mediating neurotoxicity. Journal of
Neurochemistry 130:291-300.
Strooper. 2006. Presenilin clinical mutations can affect gamma-secretase activity by different
Normal Biology and Roles in Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine
2:23.
75. Deane, R., A. Sagare, K. Hamm, M. Parisi, S. Lane, M. B. Finn, D. M. Holtzman, and B. V. Zlokovic.
Willson, J. L. Collins, J. C. Richardson, J. D. Smith, T. A. Comery, D. Riddell, D. M. Holtzman, P.
Neuron 58:681-693.
77. Koistinaho, M., S. Z. Lin, X. Wu, M. Esterman, D. Koger, J. Hanson, R. Higgs, F. Liu, S. Malkani, K.
R. Bales, and S. M. Paul. 2004. Apolipoprotein E promotes astrocyte colocalization and
Fisher, and A. Strydom. 2015. A genetic cause of Alzheimer disease: mechanistic insights from
Moeschler, M. J. Pettenati, S. M. Pueschel, K. W. Rao, L. G. Shaffer, M. Shohat, A. J. Van Riper, D.
architecture of Down syndrome phenotypes revealed by high-resolution analysis of human
segmental trisomies. Proceedings of the National Academy of Sciences of the United States of
America 106:12031-12036.
80. Prasher, V. P., M. J. Farrer, A. M. Kessling, E. M. C. Fisher, R. J. West, P. C. Barber, and A. C.


147. Yan, J., and Z. Y. Chen. 2013. BLOCKING GSK3 ss-MEDIATED DRP1 PHOSPHORYLATION PROVIDES NEUROPROTECTION AND RESCUES MEMORY DEFICITS IN APPSWE/PS1DE9 TRANSGENIC MICE. Clinical and Experimental Pharmacology and Physiology 40:3-3.


   beta-Amyloid Peptides with Cholesterol: Mechanistic Insights into Amyloid Pore Formation. 
   Biochemistry 53:4489-4502.
   Proceedings of the National Academy of Sciences of the United States of America 102:10427-
   10432.
   Bexarotene Blocks Calcium-Permeable Ion Channels Formed by Neurotoxic Alzheimer’s beta- 
   2014. Nature of the neurotoxic membrane actions of amyloid-beta on hippocampal neurons in 
   share structural and functional homology with amyloid oligomers. Neuromolecular Medicine 
   9:270-275.
   Oligomers with Anionic Lipid Bilayer and Resulting Membrane Leakage: An All-Atom Molecular 
   cholesterol-assisted oligomeric channel formation by a short Alzheimer beta-amyloid peptide. 
   between nitric oxide and dementia of the Alzheimer’s type. Brain Research Reviews 35:73-96.
174. Lipton, S. A., Y. B. Choi, Z. H. Pan, S. Z. Lei, H. S. V. Chen, N. J. Sucher, J. Loscalzo, D. J. Singel, 
   NEURODESTRUCTIVE EFFECTS OF NITRIC-OXIDE AND RELATED NITROSO-COMPOUNDS. Nature 
   364:626-632.
175. Vodovozov, Y., M. S. Lucia, K. C. Flanders, L. Chesler, Q. W. Xie, T. W. Smith, J. Weidner, R. 
   nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease. Journal of 
   Experimental Medicine 184:1425-1433.
   Biochemistry 50:3405-3407.


